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Abstract 
Rationale: Given the high prevalence and large burden of psychiatric disorders 
it is imperative to determine the underling etiology in order for better 
understanding and treatment. The neurotransmitter serotonin (5-HT) has been 
associated with mental disorders in humans both pharmacologically and 
genetically. Individuals with the short-allele of a prominent polymorphism 
within the 5-HT transporter (SERT) show increased incidence of mood disorders 
and drug dependence. However, whether or not dysregulation in the 5-HT system 
causes, or is just associated with, psychiatric disorders is impossible to determine 
from human studies alone. Consequently, it is imperative to employ an animal 
model of down-regulated SERT function. To better understand the role of 5-HT 
in drug dependence, the rat’s behavioural response to the psychostimulant (±) 3, 
4-methylenedioxymethamphetamine (MDMA), a preferentially serotonergically 
mediated drug, was assessed. Finally, the ability to rescue the anxiety-like 
phenotype in the SERT-/- rat by altering extracellular 5-HT during early 
development was also evaluated. 
Objective: The primary objective of the current thesis was to determine whether 
dysregulation of 5-HT is directly linked to the occurrence of psychiatric 
disorders, particularly drug dependence and anxiety.  
Methods: A model of down-regulated SERT function, the SERT knock-out (SERT-
/-) rat, was used for all experiments in order to determine a causal relationship 
between 5-HT dysregulation and psychiatric disorders. In Chapter 2, the 
response of the SERT-/- rats to various tasks usually disrupted by MDMA was 
assessed. In Chapter 3, the sensitivity of the SERT-/- rats to the reinforcing effects 
of MDMA was determined using the self-administration paradigm. Finally, in 
Chapter 4, whether the anxiety-like behaviour of the SERT-/- rat could be rescued 
through normalising excessive extracellular 5-HT neonatally was assessed. An 
attempt was also made to determine a mechanism by which 5-HT dysregulation 
could alter behaviour.  To this end, gene expression previously found to be up- or 
down-regulated in the SERT-/- rat was assessed in the neonatally treated rats. 
Results: The results of Chapter 2 indicated the SERT is necessary for MDMA’s 
disruption of startle habituation but not its psychomotor effects. Moreover, for 
those rats that could discriminate low dose MDMA from saline, genetic removal 
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of the SERT resulted in the inability to discriminate MDMA from amphetamine, 
implying that, in these rats, MDMA was now subjectively indistinguishable from 
amphetamine. Indeed, this alteration also resulted in enhanced sensitivity to the 
reinforcing properties of MDMA, giving MDMA the qualities of a traditional 
psychostimulant in SERT-/- rats (Chapter 3). Finally, lowering the excessive 5-HT 
during neonatal development in SERT-/- rats led to a rescue of mild, but not high, 
anxiety-like behaviour in males. However, mRNA levels of long 3’NTR BDNF and 
5-HT1a, genes associated with neurodevelopment, remained unchanged across 
genotypes and treatment groups (Chapter 4).  
Conclusions: Genetic removal of the 5-HT transporter results in an altered 
behavioural response to MDMA, in particular an increased sensitivity to its 
reinforcing properties. However, while the genetic removal of the SERT results in 
enhanced extracellular 5-HT, the pathological phenotypes present in this rat are 
likely due to this increase occurring in early development, not its continued 
presence in adulthood. Overall, these findings contribute to the growing body of 
literature indicating that enhanced brain 5-HT during early development can lead 
to pathological behaviour in adulthood.  
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Chapter 1: General Introduction 
Approximately 1 in 3 New Zealanders has experienced some form of 
mental illness. Of those individuals, approximately half are diagnosed with 
depression, anxiety, or bipolar disorder (Ministry of Health, 2013; Oakley 
Browne, Wells, & Scott, 2006). Astonishingly, 47% of the population are 
predicted to meet the criteria for some form of psychiatric disorder within their 
lifetime (Oakley Browne et al., 2006). In addition to the emotional burden, the 
OECD states the direct and indirect costs associated with mental illness, such as 
treatment costs and loss of productivity, can exceed 4% of Gross Domestic 
Product (OECD, 2014). Consequently, it is imperative research focuses on 
reducing this burden. It is important then to understand the underlying etiology 
of mental illness in order to both allow the creation of more effective targeted 
treatments and to gain better insight into risk factors. 
The neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) has 
been associated with a wide range of psychiatric disorders. For instance, 
selective 5-HT reuptake inhibitors (SSRIs, such as fluoxetine, trade name 
Prozac), which increase synaptic 5-HT through preventing its reuptake back 
into the presynaptic neuron, are commonly used to treat a myriad of disorders, 
including major depressive disorder, anxiety disorder, obsessive-compulsive 
disorder (OCD), bulimia nervosa, and panic disorder. Moreover, SSRI use during 
pregnancy, particularly during the first trimester, has been associated with 
autism in boys (Harrington, Lee, Crum, Zimmerman, & Hertz-Picciotto, 2014). 5-
HT is also postulated to play a role in drug dependence, with SSRIs found to 
decrease the reinforcing efficacy of both cocaine and amphetamine in rodents 
(Carroll, Lac, Asencio, & Kragh, 1990a; Leccese & Lyness, 1984). 
5-HT was first isolated and named in 1948 following its recognition as a 
vasoconstrictor (Rapport, Green, & Page, 1948). Since then, its wide ranging role 
in the body has been recognised, most notably in neuronal development and the 
regulation of reward related processes such as emotion, food intake, and sexual 
desire (Cools, Roberts, & Robbins, 2008; Gaspar, Cases, & Maroteaux, 2003; 
Pfaus, 2009; Vitalis & Parnavelas, 2003; Wirtshafter, 2001). 5-HT is synthesised 
in two steps: 1) the essential amino acid l-tryptophan is metabolized into 5-
hydroxy-l-tryptophan (5-HTP) by the rate-limiting enzyme tryptophan 
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hydroxylase; and 2) 5-HTP is converted into 5-HT by the enzyme L-amino acid 
decarboxylase. Being an essential amino acid, L-tryptophan must be obtained 
from the diet, with deficiencies leading to depletions of 5-HT in the brain. 
Following this pathway, 5-HT is then metabolised into 5-Hydroxyindoleacetic 
acid (5-HIAA). 5-HT is widely expressed throughout the brain, with serotonergic 
neurons centred in the raphe nuclei projecting to many brain regions, including 
the cerebral cortex, hippocampus, basal ganglia, and cerebellum. 5-HT 
neurotransmission is regulated in a number of ways; at least 15 different 5-HT 
receptors have been discovered that mediate the serotonergic signal. Of these 
receptors, the most widely spread throughout the brain is the G-protein coupled 
5-HT1a receptor. In the raphe nuclei 5-HT1a receptors are mostly 
autoreceptors located on 5-HT cell bodies: synaptic 5-HT interacts with 5-HT1a 
autoreceptors, the activation of which leads to hyperpolarisation of the pre-
synaptic neuron, resulting in decreased 5-HT release. Extracellular 5-HT is also 
regulated by the 5-HT reuptake transporter (SERT), which acts by taking 5-HT 
back up into the presynaptic neuron where it is repackaged into vesicles and 
recycled, with remaining synaptic 5-HT metabolized by monoamine oxidase A. 
Genetic epidemiological studies further support a role for 5-HT in 
psychiatric illness, demonstrating that genetic disruptions in the serotonergic 
system can lead to a wide range of psychiatric disorders. The most studied of 
these genetic disruptions is the serotonin transporter gene-linked polymorphic 
region (5-HTTLPR). The SERT protein is coded by a single gene, solute carrier 6 
number 4 or SLC6A4, located on chromosome 17 (Kenna et al., 2012). Humans 
exhibit a genetic polymorphism in this gene that results in either a 43 base pair 
deletion (short-, or s-allele) or insertion (long-, or l-allele) in the promoter 
region (Heils et al., 1996; Wendland, Martin, Kruse, Lesch, & Murphy, 2006). The 
presence of the l-allele leads to increased transcriptional efficiency, resulting in 
increased production of SERT messenger ribonucleic acid (mRNA) and 
subsequent reuptake of 5-HT from the synaptic cleft (Heils et al., 1996; Lesch et 
al., 1996). Indeed, cultured human lymphoblast cells transfected with the s-
allele exhibit a 50% reduction in [3H]5-HT uptake compared with those 
homozygous for the l-allele (l/l) (Lesch et al., 1996). Furthermore, post-mortem 
brain sample analyses indicate that SERT mRNA is lower in s-allele carriers 
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(Little et al., 1998), while in vivo imaging has demonstrated decreased SERT 
availability in these individuals (Heinz et al., 2000). 
The s-allele, carried by approximately 40% of individuals in Caucasian 
populations, was first associated with neuroticism and has since been 
associated with related affective disorders, including anxiety, bipolar disorder, 
and major depression following stressful life events (Caspi et al., 2003; Heils et 
al., 1996; Lesch et al., 1996; Sen, Burmeister, & Ghosh, 2004) for review see 
Kenna et al. (2012)). The homozygous s-allele (s/s) genotype has also been 
associated with resistance to SSRI treatment in depression (Serretti, Kato, De 
Ronchi, & Kinoshita, 2006). Moreover, the presence of the s-allele has been 
associated with the abuse of cocaine, methamphetamine and heroin (Cao, 
Hudziak, & Li, 2013; Enoch, Gorodetsky, Hodgkinson, Roy, & Goldman, 2011; 
Gerra et al., 2007). While there has been some inconsistency in the replication of 
the above findings (e.g. Jorm et al. (1998)), it is possible these discrepancies are 
due to methodological differences, particularly in regard to participant 
populations and measurements used. For instance, differences between 
ethnicities can dramatically alter findings. While the s-allele is more prominent 
in Asian populations than Caucasian, with 70% of Asian individuals carrying the 
s-allele, Asian individuals are not more likely to suffer from affective disorders 
(Weissman et al., 1996). Moreover, studies using African American populations 
demonstrate the l-allele as the risk allele, as opposed to the s-allele (Cao et al., 
2013). Additionally, the subjective and indefinite nature of retrospective self-
report used to measure variables such as anxiety calls into question the validity 
of currently described genotype differences. However, when more robust 
endophenotypes are considered, a genotype effect is still present. For example, 
s-allele carriers display increased baseline amygdala reactivity that correlates 
positively with life stress, potentially indicative of heightened rumination (Canli 
et al., 2006). 
Since the discovery of the 5-HTTLPR, other SLC6A4 variants have been 
discovered and linked to psychiatric disorders, with some revealing previously 
unknown associations between the 5-HTTLPR and mental illness (Murphy & 
Moya, 2011). Notably, recent evidence suggests that the bi-allelic distinction 
typically used when investigating the 5-HTTLPR may underestimate the 
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associated psychopathology.  Although individuals are typically parsed into s-
allele carrying versus l/l groups for comparison, an adenosine/guanine single 
nucleotide polymorphism (SNP), rs25531, predominately found within the l-
allele repeat, has been described which separates the l-allele into LA (high SERT 
expressing) and LG (low SERT expressing and comparable to the s-allele (Hu et 
al., 2005). While the bi-allelic comparison yields no clear association between 
OCD and either the s- or l-alleles, the LA/LA genotype occurs twice as often in 
individuals with OCD (Hu et al., 2005). While this finding has not been 
consistent (Wendland, Kruse, Cromer, & Murphy, 2007), when the SNP rs25532 
(also found within the 5-HTTLPR) is included in analyses, the allele associated 
with increased SERT activity is more common in individuals with OCD when 
occurring alongside the LA allele  (Wendland et al., 2008). Consequently, it is 
likely that pooling the two l-alleles may underestimate true associations. 
Other polymorphisms found within the SLC6A4 gene have also been 
associated with psychiatric disorders. One more commonly studied is the 
variable number tandem repeat identified in the second intron (STin2) of the 
SLC6A4, which contains 7, 9, 10 or 12 repeats of a 17 base pair sequence (Fan & 
Sklar, 2005). The 12 base pair repeat has been associated with schizophrenia 
and bipolar disorder, while the 9 base pair repeat has been associated with 
major depression (Fan & Sklar, 2005; Kunugi et al., 1996; Ogilvie et al., 1996). 
Additionally, an uncommon polymorphism in the coding region of the SLC6A4, 
the SNP I425V, has been linked with OCD, Asperger’s syndrome, autism 
spectrum disorder, and anorexia nervosa (Ozaki et al., 2003). Moreover, 
polymorphisms occurring in the genes of some 5-HT receptors have also been 
linked to psychiatric disorders e.g. (Seneviratne et al., 2013; Unschuld et al., 
2007). 
It is important to note, that while many of the polymorphisms occurring 
in 5-HT associated genes have been linked to particular disorders, the 
functional consequence of the polymorphism is not always known. For instance, 
although the STin2 12 base pair repeat is suspected to act as a transcriptional 
regulator (MacKenzie & Quinn, 1999), its exact biological function remains 
unknown (Fan & Sklar, 2005). Conveniently, genetically engineered rodent 
models have been created for which the exact transporter function is known. 
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Both SERT knock-out (SERT-/-) mice and rats, which have no SERT function 
whatsoever, exhibit similar pathological phenotypes to humans carrying low 
functioning SERT polymorphisms, as discussed in greater detail below (Holmes, 
Yang, Lesch, Crawley, & Murphy, 2003; Olivier et al., 2008). 
Overall, there is considerable genetic evidence that disruptions in the 
serotonergic system lead to a wide range of psychiatric impairments. However, 
the exact mechanism underlying this relationship is unclear. Given the 
pathological phenotypes found in both s-allele carriers and SERT-/- rodents, one 
might conclude that, despite the aforementioned association between increased 
serotonergic function and OCD/alcoholism, down-regulation of the SERT, and 
the resulting increase in extracellular 5-HT, plays a causative role in the 
accompanying psychiatric disorders. Paradoxically however, SSRIs, which also 
lead to an increase in extracellular 5-HT, lead to a decrease in anxiety, 
depression, and the reinforcing efficacy of drugs of abuse (Carroll et al., 1990a; 
Leccese & Lyness, 1984; Magni et al., 2013). Given that these genetic alterations 
occur from very early on in development, it is possible that these long lasting 
functional consequences are in fact adaptations from variations in brain 
development (Alexandre et al., 2006; Olivier et al., 2008).  
Indeed, alterations in 5-HT during development have previously been 
shown to lead to pathological behaviours in offspring. For instance, neonatal 
SSRI use has been associated with a 3-fold increase in autism spectrum disorder 
in boys (Harrington et al., 2014), and increased behavioural problems in 3 year 
olds (Oberlander et al., 2010). However, no studies have yet tracked offspring 
into adulthood, so it is unknown whether further problematic phenotypes 
develop. More importantly, due to the comorbidity of affective disorders such as 
depression and anxiety in these mothers, it is difficult to ascribe any increased 
risk in negative outcomes in offspring to prenatal SSRI use directly. However, 
animal studies, in which it is much easier to both track offspring and control 
extraneous variables, have also linked early life 5-HT alterations to pathological 
phenotypes in adulthood (Ansorge, Morelli, & Gingrich, 2008; Ansorge, Zhou, 
Lira, Hen, & Gingrich, 2004; Forcelli & Heinrichs, 2008; Olivier et al., 2011; 
Zhang et al., 2006). For instance, postnatally decreasing 5-HT through depletion 
of the 5-HT precursor L-tryptophan in rats leads to an increase in anxiety- and 
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depression-like phenotypes in adulthood, as indicated by performance in the 
forced swim test (FST), and the elevated plus maze (EPM) (Zhang et al., 2006). 
Moreover, increases in 5-HT following administration of fluoxetine during early 
development (both pre- and post-natally) produces an anxiety-like phenotype 
in the novelty suppressed feeding (NSF), open field, and EPM tasks (Ansorge et 
al., 2008; Ansorge et al., 2004; Forcelli & Heinrichs, 2008; Olivier et al., 2011). 
Moreover, these offspring show increased sensitivity to cocaine, exhibiting 
increased cocaine-induced conditioned place preference (CPP) and increased 
resistance to extinction following cocaine self-administration (Forcelli & 
Heinrichs, 2008). At the present time there is uncertainty regarding why these 
disruptions can be associated with very different psychiatric illnesses in 
humans. It is, for instance, unclear why some s-allele carriers become 
depressed, while others become addicted to drugs of abuse. It is likely the 
interaction between these genetic disruptions and the environment plays a role 
(Caspi et al., 2003).  
To better understand why disruptions in the serotonergic system lead to 
psychiatric illness, genetic disruptions in the SERT must be thoroughly 
investigated. While it is important to consider data from humans, the necessary 
correlational nature of the data limits what can be concluded about the causal 
role of any polymorphisms. Moreover, in addition to the subjective nature of 
mental illness measures, the multitude of various SNPs within the SLC6A4, as 
well as further distinct genetic factors, means there is a low level of control over 
the experimental group. Consequently, it is important to use animal models to 
complement evidence from human studies.  Animal models for the SERT 
polymorphism include SERT-/- mice (Bengel et al., 1998). SERT-/- mice show a 
60-80% reduction in tissue 5-HT, and increased extracellular 5-HT (Bengel et 
al., 1998; Fabre et al., 2000). Moreover, as with s-allele carriers, they display 
anxiety-like behaviour, as indicated by their performance in the EPM, open field, 
and home cage emergence tasks compared to wild type (SERT+/+) littermates 
(Holmes et al., 2003). While results are mixed in tests of behavioural despair 
(FST, tail suspension test) (Holmes, Yang, Murphy, & Crawley, 2002; Lira et al., 
2003), the more robust sucrose preference test, a measure of anhedonia, reveals 
no depression-like phenotype in SERT-/- mice (Kalueff, Gallagher, & Murphy, 
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2006). Both cocaine- and (+)-amphetamine-induced locomotor activity is 
unaltered in SERT-/- mice (Bengel et al., 1998; Sora et al., 2001). Moreover, while 
SERT-/- mice show enhanced cocaine-induced CPP (Sora et al., 1998), (+)-
Methylenedioxymethamphetamine- (MDMA) induced locomotor activity and 
racemic MDMA self-administration are extinguished (Bengel et al., 1998; Trigo 
et al., 2007).  
Although these mice show high phenotypic similarities with s-allele 
carriers, there are differences between mice and other species, which leaves 
some reservations as to what can be concluded. For instance, rats and mice 
exhibit differential physiological responses to the 5-HT1a antagonist 8-OH-
DPAT. While the 5-HT1a antagonist 8-OH-DPAT induces hypothermia in both 
mice and rats, this is mediated by the presynaptic 5-HT1a auto receptor in the 
mice, but the postsynaptic 5-HT1a receptor in rats (Bill, Knight, Forster, & 
Fletcher, 1991). Furthermore, MDMA produces differential long term effects in 
mice and rats. For instance, racemic MDMA acts as a selective DA neurotoxin in 
mice, leading to a decrease in striatal DA and its metabolites, as well as 
significantly reducing DAT, with minimal effects on 5-HT (Colado, O’Shea, & 
Green, 2004; Kindlundh-Högberg, Schiöth, & Svenningsson, 2007; O'Callaghan & 
Miller, 1994; O'Shea, Esteban, Camarero, Green, & Colado, 2001). Whereas in 
humans, non-human primates, and rats, there is evidence that long-term use of 
MDMA leads to selective 5-HT depletion and a decrease in SERT expression, 
increasing the addictive potential of MDMA (Buchert et al., 2004; Easton & 
Marsden, 2006; Kindlundh-Högberg et al., 2007; O'Shea, Granados, Esteban, 
Colado, & Green, 1998). Thus, the rat model is more consistent with the effects 
of MDMA in humans. Consequently, it is useful to also consider the behavioural 
effects of MDMA in a rat model. Such a model was created in 2006 using the 
mutagen N-ethyl-N-nitrosourea or ENU (Smits et al., 2006). ENU was 
intraperitoneally injected into male rats resulting in random point mutations, 
primarily in spermatogonial stem cells. Following breeding with healthy, 
untreated, females, the first generation was screened for genes of interest, 
which resulted in the discovery of a female with a point mutation in the SLC6A4 
gene. This mutation produced a premature stop codon, resulting in a complete 
eradication of SERT mRNA from these animals due to nonsense mediated RNA 
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decay. SERT-/- rats have no SERT protein as indicated by radioactively labelled 
citalopram binding, and consequently 5-HT uptake is reduced by 72% in 
hippocampal synaptosomes (increasing to 100% with the addition of a 
norepinephrine transporter (NET) blocker), and extracellular 5-HT in the 
hippocampus is increased 9-fold as determined by microdialysis (Homberg et 
al., 2007). There are no compensatory changes in monoamine oxidase A activity 
in either the cortex or Caudate Putamen following this increased extracellular 5-
HT. Moreover, tissue 5-HT levels are reduced to ~50-75% and 5-HIAA levels are 
reduced to ~45-55% in the hippocampus, caudate putamen, cortex, and 
amygdala (Homberg et al., 2007). However, 5-HT neurons in the dorsal raphe 
nuclei remain unchanged (Olivier et al., 2008). The heterozygous variant 
(SERT+/-) displays a 50% reduction in SLC6A4 resulting in a 40% reduction in 
radioactively labelled citalopram binding, with 5-HT uptake reduced by 13.4% 
(Homberg et al., 2007). Both DA transporter (DAT) and NET concentrations, as 
well as uptake and concentrations of DA, norepinephrine (NE), and their 
metabolites (aside from NE levels in the amygdala), remain unchanged in SERT-
/- ex vivo (Homberg et al., 2007). However, in vivo the response of SERT-/- rats to 
NET and DAT blockers is altered compared to SERT+/+ rats: In SERT-/- rats, but 
not SERT+/+ rats, the DAT blocker GBR12909 induces prolonged hyperthermia, 
and low doses of the NET blocker atomoxetine attenuate stress-induced 
hyperthermia (Olivier, Cools, Deen, Olivier, & Ellenbroek, 2010). Similar to mice, 
SERT-/- rats display an anxiety-like phenotype in the open field, EPM, home cage 
emergence, and NSF (males only) tasks (Olivier et al., 2008). A depression-like 
phenotype is also apparent in the FST and sucrose preference task (Olivier et al., 
2008). Moreover, SERT-/- rats are more sensitive to the reinforcing properties of 
cocaine, as demonstrated by increased self-administration of cocaine at low 
doses, increased breakpoint for progressive ratio at high doses, and increased 
cocaine-induced CPP compared with SERT+/+ littermates (Homberg et al., 2008). 
Unlike SERT-/- mice, SERT-/- rats also displayed increased cocaine-induced 
locomotor activity, which at low doses was potentiated by the 5-HT1a agonist 8-
OH-DPAT (Homberg et al., 2008; Sora et al., 2001). It is likely that compensatory 
changes in the 5-HT1a receptor, likely the desensitisation of the 5-HT1a 
receptor (Homberg et al., 2008), facilitate the reinforcing effects of cocaine at 
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low doses. Given their functional and behavioural similarities to humans with 
the s-allele, SERT-/- rats are a good candidate to model this variant. While it is 
important to note the heterozygous animals are more representative of the s/s 
genotype, it is crucial to initially perform tests with the full knockout model to 
validate any initial hypotheses before moving onto the less extreme version of 
altered SERT function.  
While these findings support the notion that the serotonergic system 
plays a role in the reinforcing efficacy of cocaine, it is important to note that 
cocaine is particularly reinforcing. Consequently, increases in the reinforcing 
efficacy from SERT+/+ to SERT-/- are small. In order to better tease apart the 
underlying consequences of the lack of SERT on drug addiction, it is pertinent 
that the reinforcing effects of different, less rewarding, drugs of abuse are 
assessed. A promising candidate is MDMA, the main psychoactive component of 
the street drug ecstasy. MDMA, commonly used for its ability to produce 
euphoria, enhanced sensory perception, as well as feelings of well-being and 
self-confidence, has long been thought of as a safe, non-addictive drug. However, 
recent studies have shown prevalence rates are increasing, with New 
Zealanders amongst the highest consumers of MDMA in the world (UNODC, 
2012). Moreover, MDMA has been found to be self-administered in rats, mice 
and monkeys, highlighting its abuse potential (Schenk, 2009). Indeed, while the 
addictive potential of MDMA is now well recognised, it is lower than that of 
most other drugs of abuse. While virtually all animals will readily learn to self-
administer cocaine, only ~50% will learn to self-administer MDMA 
(Fantegrossi, Ullrich, Rice, Woods, & Winger, 2002; Schenk et al., 2007). This is 
likely due to MDMA’s larger influence on the serotonergic system compared 
with other psychostimulants (Cole & Sumnall, 2003; Crespi, Mennini, & Gobbi, 
1997; Han & Gu, 2006). While MDMA exerts its effects by blocking and inducing 
reverse transport of SERT, DAT, and NET, it has a much higher affinity for SERT 
relative to DAT, in contrast with cocaine, amphetamine, and methamphetamine, 
which all have a higher affinity for DAT (Han & Gu, 2006). It has repeatedly been 
shown that increasing 5-HT leads to a reduction in the rewarding properties of 
drugs of abuse (Baumann et al., 2011; Carroll et al., 1990a), while decreasing 5-
HT leads to an increase in such properties (Carroll, Lac, Asencio, & Kragh, 
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1990b; Leccese & Lyness, 1984; Pelloux, Dilleen, Economidou, Theobald, & 
Everitt, 2012). Indeed, previous studies indicate 5-HT inhibits DA-mediated 
effects (Baumann et al., 2011; Rothman & Baumann, 2006). However, the exact 
role of 5-HT in regulating drug intake is still unknown. 
Taking into consideration MDMA’s increased affinity for the 5-HT 
system, and 5-HT’s dampening on the dopaminergic effects of drugs of abuse, it 
would be interesting to see whether SERT-/- rats display an increased 
propensity to self-administer MDMA. While it is curious that SERT-/- mice failed 
to self-administer MDMA, this bears repeating in a rat model given the 
aforementioned differences between mice and rats in the response to MDMA 
(Kindlundh-Högberg et al., 2007; Koch & Galloway, 1997; O'Shea et al., 2001). 
While abuse of MDMA has not been considered in individuals with low activity 
5-HTTLPR genotypes, use of MDMA is not significantly higher in individuals 
with the s-allele (Martín-Santos et al., 2010; Roiser, Cook, Cooper, Rubinsztein, 
& Sahakian, 2005), although there was a trend for increased use in s/s 
genotypes in Martín-Santos et al. (2010). Given that these studies used the 
biallelic distinction of the 5-HTTLPR, which fails to account for additional l-
allele polymorphisms that also lead to a reduction in SERT activity, any existing 
differences may be underestimated. Moreover, there is some evidence these 
individuals may be more sensitive to the cognitive effects of ecstasy use, with s-
allele carrying ecstasy users displaying deficits in attention and decision making 
(Cuyàs et al., 2011; Roiser et al., 2005; Roiser, Rogers, Cook, & Sahakian, 2006). 
Additionally, ecstasy using s/s individuals report increased sedation compared 
to l-allele carriers following ecstasy, and are more likely to suffer from non-
substance-induced mood disorders such as depression (Martín-Santos et al., 
2010; Pardo-Lozano et al., 2012; Roiser et al., 2005). Given the small number of 
studies and their correlational nature, it is difficult to draw a firm conclusion 
from these data, other than to say there are indications that s-allele carriers 
react differently to ecstasy than l/l controls.  
It is possible that decreased SERT activity influences some of the 
behavioural effects of MDMA while leaving others uninterrupted. Indeed, MDMA 
studies in rodents have indicated that different monoamines govern different 
behavioural effects. For instance, MDMA disrupts attentional processes such as 
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habituation to a loud stimulus, which appears to be mediated by 5-HT (Kehne et 
al., 1992). However, increases in locomotor activity appear to be governed by 
both DA and 5-HT mechanisms (Daniela, Brennan, Gittings, Hely, & Schenk, 
2004; Kehne et al., 1996). Consequently, it is important to determine which of 
the behavioural effects of MDMA are altered in the SERT-/- rat.  
While confirming and extending the phenotype of SERT-/- rats is 
important, it is also crucial to determine the mechanisms underlying this 
alteration. As mentioned above, it is believed that the increased 5-HT during 
development is responsible for the pathological phenotype that characterises 
humans and rats with low SERT expression. Consequently, it is important to 
establish whether early intervention can prevent the pathological phenotype 
associated with the genetic reduction of SERT. An elegant study in SERT-/- mice 
has yielded promising results: The administration the 5-HT neurotoxin para-
chlorophenylalanine (pCPA) during early development was found to attenuate 
the effects of reduced SERT function on rapid eye movement (REM) sleep in 
adulthood in SERT-/- mice (Alexandre et al., 2006). This finding indicates that 
‘normalising’ extracellular 5-HT levels during development may rescue the 
pathological phenotype. While the effect of normalising 5-HT levels during 
development on anxiety- and depression-like behaviours in SERT-/- rodents has 
not yet been attempted, the same study found that when SERT-/- mice were 
treated with the 5-HT1a receptor antagonist WAY 100635 during early 
development their depression-like behaviour was normalised in the tail 
suspension test, indicating that prevention of 5-HT1a stimulation can reverse 
the depression-like phenotype (Alexandre et al., 2006). Given 5-HT’s wide 
ranging role during development, including neuronal migration, division, and 
differentiation (Gaspar et al., 2003), it is likely there could be many mechanisms 
underlying this change. However, no one has yet attempted to rescue the 
phenotype for SERT-/- rats, or has attempted to elucidate precisely why 
increased extracellular 5-HT during development causes this adult phenotype. 
 
Current thesis 
Given the state of the literature, the current project has three parts, which will 
be addressed consecutively in the following three chapters: 
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1) Although MDMA increases 5-HT, DA, and NE, it is unclear in which way 
the relative contributions play a role in the behavioural efficacy of MDMA 
in the brain. This will be investigated in Chapter 2 by looking at the effect 
of MDMA in the SERT-/- rat on various behavioural tasks with a 
predominant serotonergic or dopaminergic mechanism of action.  
2) As SERT-/- rats are more sensitive to the reinforcing effects of cocaine, 
but SERT-/- mice fail to self-administer MDMA, Chapter 3 will seek to 
determine whether SERT-/- rats are more likely to self-administer MDMA 
than SERT+/+ rats, and are therefore more sensitive to the reinforcing 
effects of MDMA. 
3) To further elucidate the theory that increased 5-HT during development 
plays a role in adult phenotype, experiments presented in Chapter 4 will 
determine whether decreasing 5-HT in SERT-/- rats during development 
will rescue their anxious phenotype. Further to this, the thesis will 
attempt to elucidate the mechanism of a possible change by establishing 
if increased early life 5-HT leads to alterations in the mRNA of chosen 
candidate genes. 
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Chapter 2: The role of serotonin in the behavioural effects of MDMA 
The subjective effects of (±) 3,4-methylenedioxymethamphetamine 
(MDMA), namely feelings of wellbeing, closeness, and empathy, differ from 
those of classical psychostimulants such as cocaine and amphetamine. This 
dissociation is likely due to the distinct pharmacology of MDMA. While most 
drugs of abuse primarily exert their actions through an increase in dopamine 
(DA), MDMA preferentially increases serotonin (5-HT) compared with DA and 
norepinephrine (NE) (Han & Gu, 2006). This increased potency for the 5-
HTsystem likely underlies the decreased abuse potential of MDMA compared to 
cocaine and amphetamine. While close to 100% of animals will learn to press a 
lever for an intravenous infusion of either cocaine or amphetamine, only around 
50% will learn this for MDMA (Schenk, Gittings, Johnstone, & Daniela, 2003). In 
addition to its propensity to be self-administered by rats, MDMA has a complex 
behavioural profile. For instance, it modifies attention and movement 
(Baumann, Clark, & Rothman, 2008; Kehne et al., 1992; Padich, McCloskey, & 
Kehne, 1996). However, while MDMA increases release of 5-HT, DA, and NE, it is 
unclear what the relative contribution of each of these neurotransmitters is in 
regulating behaviour. So far, this has almost exclusively been studied using 
pharmacological tools, i.e. by more or less selectively blocking specific 
receptors.   
First, MDMA disrupts attentional processes (Kehne et al., 1992; Padich et 
al., 1996). For instance, acute MDMA interrupts sensorimotor gating, the 
regulation of sensory information to the motor cortex (Padich et al., 1996). 
Sensorimotor gating is commonly measured through pre-pulse inhibition (PPI), 
which refers to the ability of a weak stimulus immediately preceding a startle 
stimulus to inhibit the usual response to that startle stimulus (Graham, 1975). 
Interruption of auditory PPI by MDMA appears to be governed by 5-HT, with 
blockade of the 5-HT2a receptor, but not the DA D2 receptor, attenuating 
MDMA-induced disruption of auditory PPI (Padich et al., 1996). Also interrupted 
by MDMA is startle habituation, the eventual habituation to a startle stimulus 
following repeated exposure (Moyer, 1963). MDMA dose dependently decreases 
habituation to both acoustic and tactile startle stimuli, an effect prevented by 
both serotonergic neurotoxicity as well as the SSRI fluoxetine, but not by NE 
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transporter or DA D2 receptor blockade (Kehne et al., 1992). Overall, these 
particular attentional processes appear to be serotonergically mediated. 
However, these conclusions are tentative given the limited number of studies 
performed.  
Second, MDMA has been demonstrated to alter locomotor activity 
(Baumann et al., 2008; Colussi-Mas & Schenk, 2008; Daniela et al., 2004; Gold, 
Koob, & Geyer, 1988; Kehne et al., 1996; Spanos & Yamamoto, 1989). For 
instance, acute MDMA dose dependently increases forward locomotion as well 
as stereotyped behaviours characteristic of 5-HT syndrome, such as forepaw 
treading, head weaving and low body posture (Gold et al., 1988; Spanos & 
Yamamoto, 1989). It is unclear however, whether this alteration of movement is 
mediated by serotonergic or dopaminergic mechanisms. For instance, increases 
in both 5-HT and DA have been correlated with MDMA-induced increases in 
stereotypy and ambulation (Baumann et al., 2008). Moreover, blockade of the 
either the DA D1 or the 5-HT2a receptor abolishes MDMA-induced locomotor 
activity in rats (Daniela et al., 2004; Kehne et al., 1996). Repeated exposure to 
MDMA produces a sensitised locomotor response (Colussi-Mas & Schenk, 2008; 
Ramos, Goñi-Allo, & Aguirre, 2004; 2005 2005; Spanos & Yamamoto, 1989), 
which also appears to involve a complex interaction between 5-HT and DA. For 
instance, while blockade of the DA D1 receptor by SCH23390 prevented the 
expression of MDMA-induced sensitisation, follow up studies have indicated 
this effect is due to the action of this antagonist on 5-HT2A receptors, not the D1 
receptor (Ramos et al., 2004, 2005). Thus these findings demonstrate a complex 
behavioural profile for the involvement of MDMA in movement yet to be fully 
elucidated. 
Last, as mentioned, the subjective effects of MDMA differ from those of 
classical psychostimulants. Indeed, in the drug discrimination paradigm, in 
which rats are taught to associate an operant response with a particular 
substance, rats can learn to differentiate MDMA and d-amphetamine (Goodwin 
& Baker, 2000; Harper, Langen, & Schenk, 2014), indicating the subjective 
properties of MDMA and amphetamine dissociate, at least at low doses of 
MDMA. While this makes sense given the preferential serotonergic affinity of 
MDMA, when rats are trained to distinguish MDMA from saline, d-amphetamine 
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partially generalises to MDMA (Oberlender & Nichols, 1988; Schechter, 1988), 
although MDMA does not generalise to d-amphetamine in d-amphetamine 
trained rats (Oberlender & Nichols, 1988). More recent investigations have 
revealed that, while doses of MDMA equal to and lower than the MDMA training 
dose generalise to MDMA, higher doses generalise to amphetamine (Harper et 
al., 2014), suggesting a complex interaction between 5-HT and DA in the 
subjective profile of MDMA. Indeed, both DA and 5-HT antagonists have been 
found to decrease the discriminative stimulus properties of MDMA in MDMA 
trained rats (Schechter, 1988). However, the relative contribution of DA and 5-
HT in the subjective effects of MDMA is still far from clear. 
Pharmacological studies are widely criticised for their non-specificity. 
For instance the D1 receptor antagonist SCH23390 also binds to the D5, 5-HT1a, 
and 5-HT2c receptors (Millan, Newman-Tancredi, Quentric, & Cussac, 2001; 
Ramos et al., 2005). In addition, there are 5 dopaminergic receptors and at least 
15 5-HT receptors. Since MDMA is an indirect agonist (i.e. it enhances the 
release of 5-HT and DA), it could, in theory, act on all these receptors. Moreover, 
in the locomotor activity paradigm, it is possible that some antagonists have 
locomotor depressant effects when administered alone, such as DA D2 receptor 
antagonists (Millan, Seguin, Gobert, Cussac, & Brocco, 2004), an effect difficult to 
ascertain due to the low baseline locomotion in saline comparison groups. It is 
desirable then to use a method known not to have locomotor depressant effects. 
Therefore, in order to further discern the relative contributions of 5-HT, DA, and 
NE in the behavioural effects of MDMA, we decided to make use of a genetic 
model, the 5-HT reuptake transporter knock-out (SERT-/-) rat. It has been 
shown previously that this rat lacks a functional SERT and as a result is 
insensitive to the effects of the selective 5-HT releaser fenfluramine (Homberg 
et al., 2008). Consequently, it is anticipated that behaviours in which the 
disruption by MDMA has been previously proposed to be serotonergically 
mediated (PPI, startle habituation, possibly stereotypy) will be abolished in 
these rats. Given the apparent role of both 5-HT and DA in forward locomotion 
following MDMA, the SERT-/- rat will be useful in determining whether 5-HT is 
necessary for the locomotor activating and/or sensitising effects of MDMA. 
Finally, given that MDMA is unable to release 5-HT in these animals whatsoever, 
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it is anticipated that the subjective effects of MDMA would resemble those 
induced by amphetamine and thus in the drug discrimination paradigm, we 
predict that amphetamine be indistinguishable from MDMA in the SERT-/- rats.  
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Method 
Subjects 
Serotonin transporter knockout rats (SLC6A41Hubr, SERT-/-) were 
originally created via N-ethyl-N-nitrosourea (ENU)-induced mutagenesis in a 
commercial (Harlan, Ter Horst, The Netherlands) wild-type Wistar rat (Smits et 
al., 2006). Experimental animals were generated by breeding pairs of SERT-/- or 
wild-type (SERT+/+) animals who had been bred by crossing heterozygous 
animals (SERT+/-) that had been outcrossed for at least 10 generations. Parent 
animals had been previously genotyped at 3 weeks of age.  Ear samples were 
taken following the administration of anaesthesia produced by isoflurane and 
used for genotyping (See Smits et al. (2006) for a more detailed description). 
Experimentally naïve adult male rats were used for consecutive experiments. 
Female rats were not used in the current set of experiments due to unpublished 
findings from our lab that indicate self-administered MDMA significantly 
increased mortality in female rats. Animals were bred and reared at the 
vivarium of the School of Psychology at Victoria University of Wellington. 
Animals were housed in groups of 3 to 6 until they reached 200 - 250 g, at which 
point they were housed in pairs in hanging polycarbonate cages in a 
temperature (19 - 21 oC) and humidity (55%) controlled room. For PPI and 
locomotor activity testing, animals were kept on a normal 12 hr light/dark cycle 
(lights on from 07.00 – 19.00 h), with testing being conducted during the light 
phase. For drug discrimination testing, animals were kept on a reverse 12 hr 
light/dark cycle (lights on from 19.00 – 07.00h), with testing being conducted 
during the dark phase. Aside from testing hours, water and food (aside from the 
duration of the drug discrimination paradigm) was available ad libitum. All 
testing environments were temperature (19 - 21 oC) and humidity (55%) 
controlled. All protocols were approved by the Victoria University of Wellington 
Animal Ethics Committee (AEC-2012R2). 
 
Apparatus and procedure 
Pre-pulse inhibition and startle habituation. Twenty-nine 
experimentally naïve adult male rats (14 SERT-/-, 15 SERT+/+) weighing 200 - 
250 g were used (7 - 8 per group). Tests were conducted in standard startle 
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equipment (San Diego Instruments, San Diego). These consisted of a clear 
Perspex cylinder, 6” (L) x 2 1⁄4” (ID), mounted on a platform with a piezo 
electrical element, housed in a sound-attenuated chamber. Trial delivery and 
data acquisition were controlled by an interfaced microcomputer using a 
commercially available software package (SR-LABTM Startle Response System, 
San Diego Instruments, San Diego).  
Sessions were conducted between 11:00 and 15:00 hours. Fifteen 
minutes prior to the session start, rats were injected with 5 mg / kg 
intraperitoneal (i.p.) MDMA or vehicle, and then placed back in their home cage. 
They were then placed in the cylinder for the duration of the sessions. Each 
session was of 20-minute duration, and began with 5 minutes of habituation 
(white noise 70 dB) followed by 71 trials. The session both began and finished 
with 5 startle trials (120dB, 20ms). In between these blocks were pre-pulse 
inhibition trials, consisting of 72, 74, 78, and 86 dB stimuli (20 ms) preceding a 
startle stimulus by 100 ms, as well as further startle stimuli, and ‘no stimulus’ 
trials. A startle response in response to the startle stimuli was measured. Given 
the results of the first set of trials, the experiment was repeated using 10 mg / 
kg i.p. following a 1 week wash-out period. In order to minimise any sustained 
effect of the acute dose of MDMA, those animals who had previously received 
saline received MDMA, and vice versa. 
Locomotor Activity. Adult male rats that had been used previously for 
PPI were given 2 weeks off, and then used for locomotor activity. In order to 
minimise drug effects, those animals that had been administered saline in the 
last 10 mg / kg MDMA in the PPI trial were allocated to the MDMA group, and 
vice versa. All apparatus and procedures used were identical to those used 
previously in our lab (Colussi-Mas & Schenk, 2008). Locomotor activity was 
assessed in open field activity systems consisting of eight clear Plexiglas activity 
chambers (42 x 42 x 30 cm) set in sound-attenuated chambers (ENV-515-16, 
Med Associates Inc., Vermont).  Location was tracked using 2 pairs of 8 evenly 
spaced infrared sources and sensors positioned perpendicular to one another 
around the chambers, and recorded by a commercially available software 
package (Med-PC IV, Med Associates Inc., Vermont). The infrared beams divided 
the chamber into squares, with a region set to the approximate dimensions of a 
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rat (3 x 3 squares) generated around the rat. Any beam breaks within this 
region were counted as stereotypy. These movements have previously been 
shown to predominantly comprise of forepaw treading and head weaving 
(Baumann et al., 2005). One ambulatory count was registered if 3 beams were 
successively broken within 1000ms outside the region. A white noise generator 
masked extraneous auditory disturbance during testing, and the room was 
illuminated with red light. Prior to and after each behavioural test session, the 
chamber interiors were cleaned and wiped with Virkon ‘S’ disinfectant 
(Southern Veterinary Supplies, Palmerston North, New Zealand).  
On each day of testing, animals were first habituated to the activity 
chambers for 30 min. They were then injected with 2.5 mg ⁄ kg i.p. MDMA or 
saline (n = 7 - 8 per group) once daily for 5 consecutive days, and then placed 
into the activity chamber for 2 hours. This dose was chosen as it was both 
relatively low while still being behaviourally active within this paradigm 
(Spanos & Yamamoto, 1989). Following a two-day withdrawal period, animals 
were given a challenge injection of saline or MDMA (2.5 mg / kg, i.p.).  
Drug discrimination. Fourteen adult male rats (7 SERT-/-, 7 SERT+/+) 
that had been used previously for PPI and locomotor activity testing were given 
3 weeks off, and then used for drug discrimination. Water was available ad 
libitum while commercial rat chow was rationed to maintain 85 - 90% free 
feeding weight. All training and testing took place in standard operant 
conditioning chambers measuring 28 x 21 x 21 cm equipped with three 
retractable levers (ENV-008, Med Associates Inc., Vermont). A sucrose pellet 
delivery apparatus was located in the centre front panel, while one lever was 
situated to the right and one to the left. A third lever was located at the centre of 
the back panel but was not used for the present experiment. Standard 100 mA 
white lights were situated above every lever. Sucrose pellet delivery and data 
acquisition were controlled by an interfaced microcomputer using a 
commercially available software package (Med-PC IV, Med Associates Inc., 
Vermont). Sucrose pellets (45 mg Dustless Precision Pellets, F0042) were 
obtained from Bio Serv (Frenchtown, NJ). 
Training began with 14 days of 30-minute autoshaping sessions which 
train the rat to associate the pressing of a lever with a sucrose reward. During 
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autoshaping sessions one of the two levers (randomly determined) was inserted 
into the chamber and the light above was illuminated for 12 seconds. If subjects 
responded, or 15 seconds had elapsed (whichever occurred first), they were 
rewarded with a sucrose pellet. Thirty seconds later a new trial was initiated. 
Subjects could receive a maximum of 60 pellets in each session. Following 10 
days, the interval for which a free pellet was dispensed following a failure to 
respond was increased to 60 seconds for four sessions in order to increase 
responding in two subjects. Finally, the fixed ratio, or the number of responses 
required to obtain a reward, was increased to 3, 5 and then 10 over three 
additional sessions. All subjects reliably responded following autoshaping. 
Discrimination training then commenced. Rats were administered 
MDMA (1.5 mg / kg) or saline i.p. at the start of each session. Training doses 
were selected on the basis of previous research (Goodwin & Baker, 2000; 
Harper et al., 2014; Schechter, 1988). MDMA and saline were given in 
pseudorandom order, with each condition administered on no more than two 
consecutive days. Sessions began with 15 minutes of no trials in order to allow 
the drug to take effect, and continued until either 60 reinforcers were gained or 
45 minutes had elapsed. For the first 15 sessions training was errorless, with 
only the drug appropriate lever presented. Following this, both levers were 
presented simultaneously, though only responses on the drug appropriate lever 
led to reward. Responses made on the alternate lever reset the response 
counter.  
All rats were run between 13:00 and 15:00 hours Monday - Friday, with 
drug-lever selection differing in half of the subjects. Subjects were required to 
meet a criterion of 85% drug appropriate lever responses, prior to the delivery 
of the first reinforcer, over 3 consecutive sessions in order to move onto the 
testing procedure. If animals had failed to meet discrimination criterion 
following 55 training sessions they were deemed not to have met criterion. 
After subjects met criterion, generalization tests with 0.5 mg / kg 
amphetamine i.p. were conducted. Sessions were identical to those performed 
in training, however sessions ceased following 10 responses and no reinforcers 
were given. Probe sessions were run 2 - 3 times with at least two standard 
training days in between. If the subject did not maintain 85% accuracy 
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generalisation tests were not recommenced until at least 2 consecutive 
discrimination days, including both MDMA and saline, met the 85% criterion.  
Data were collapsed across different sessions for the same probe condition. 
 
Drugs 
MDMA HCl and d-amphetamine were both obtained from Environmental 
Science and Research (Porirua, New Zealand). All drugs were dissolved in a 
sterile solution of 0.9% physiological saline and administered at a volume of 1 
ml / kg body weight. All weights refer to the anhydrous salt and not the acid. 
 
Data Analysis 
All statistical analyses were performed using IBM SPSS Statistics version 22 for 
windows. The alpha level for statistical significance was set at p < .05. 
Pre-pulse inhibition and startle habituation. To determine there was 
no interaction between PPI intensity and either genotype or treatment, a 
repeated measures analysis of variance (ANOVA) was initially run. Upon 
confirming there were no interactions present, PPI intensities were pooled and 
further ANOVA’s run. ANOVA tests were used for all analyses with genotype and 
treatment as fixed factors. Following this, univariate ANOVA tests were used to 
ascertain treatment effects within each genotype, with treatment entered as the 
between subjects factor. PPI scores were calculated by dividing the mean of all 
the PPI scores (2, 4, 8, and 16 dB) by the mean of the startle trials within the 
middle block and deriving a percentage change in response. Mean basal startle 
response was calculated using the average startle response following the first 
block of 120 dB stimuli. The startle habituation score was measured as the 
percentage change in basal habituation between the first and last blocks of 
startle stimuli. Post hoc tests, where appropriate, employed Tukey’s Honestly 
Significant Difference test. The Greenhouse-Geisser correction was employed in 
all cases where sphericity was violated 
Locomotor activity. To determine whether groups differed in their 
baseline locomotor activity, activity during the first 30 minutes (prior to drug 
administration) was analysed using a univariate ANOVA, with Tukey’s Honestly 
Significant Difference test used during post hoc analyses. To determine whether 
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genotypes differed overall, genotype groups were pooled (regardless of yet to 
be experienced drug condition), and another univariate ANOVA was run. A 
multivariate ANOVA was employed to determine any post treatment differences 
following both acute and repeated MDMA, with genotype and treatment entered 
as between subjects’ factors. Follow up t-tests were employed where 
appropriate. To determine whether repeated MDMA resulted in locomotor 
sensitisation, paired t-tests comparing the ambulatory counts and stereotypic 
counts following acute treatment and challenge after successive treatment of 
each genotype were undertaken. Extreme outliers were identified using SPSS’s 
outlier test and removed. 
Drug discrimination. Genotype differences in the proportion of rats 
who met the discrimination criterion were analysed using a Kaplan-Meyer 
survival curve analysis with genotype entered as the between subjects variable. 
Response rate was also assessed. A measure of average responses per second 
was obtained by averaging the time each subject took to complete the first fixed 
ratio 10 trial during their final three discrimination sessions. An independent 
samples t-test was used, with genotype entered as the between subject variable. 
The data from one SERT-/- animal was excluded due to technical difficulties in 
the recording of latency data. Further to this, proportion of responses made on 
each lever was assessed by determining the percentage of responses made on 
the saline and MDMA appropriate levers during the 10 responses in the 
amphetamine probe session.  A mixed repeated ANOVA was used, with lever as 
the within-subject variable and genotype as the between subject variable. In the 
case of a significant main effect or interaction, post hoc t-tests were used to 
determine the source of the significance, with equal variances not assumed if 
Levene’s test for equality of variances was significant. 
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Results 
Pre-pulse inhibition and startle habituation 
As animals were exposed to different treatments following the first set of 
trials, it was first ascertained whether or not the repeated exposure to stimuli 
affected either PPI or startle habituation in the saline group. For PPI scores 
there were no significant differences between genotype F1,25 = .00, p = .98, day 
of trial, F1,25 = 3.56, p = .07, or interaction, F1,25 = 1.25, p = .27. Additionally for 
startle habituation scores there were no significant differences for genotype, 
F1,25 = .17, p = .68, day of trial F1,25 = .93, p = .34, and no interaction, F1,25 = .23, p 
= .63. Consequently, the data for saline treatments between experiments were 
amalgamated. 
Table 2.1 displays mean basal startle responses of each genotype 
following pre-treatment with either saline, 5, or 10 mg / kg MDMA. No main 
effect of genotype, F1,52 = 3.06, p = .09, or treatment, F1,52 = .18, p = .84, was 
found, as well as no interaction, F1,52 = .54, p = .59, suggesting there are no 
differences between groups in terms of basal startle response. 
 
Table 2.1. 
Basal startle response in SERT +/+ and   SERT -/- animals following pre-treatment 
with either saline (14 - 15 per group), 5 or 10 mg / kg MDMA i.p (7 - 8 per group). 
Treatment SERT +/+ SERT -/- 
saline 344 ± 95.1 548 ± 124.6 
5 mg / kg MDMA 285 ± 92.8 605 ± 127.2 
10 mg / kg MDMA 362 ± 115.4 392 ± 135.1 
 
While a significant effect of PPI intensity was observed, F2.38,123.98 = 52.96, 
p = .00, there were no significant interactions present (Intensity by genotype: 
F2.38,1 23.98 = 1.09, p = .35; intensity by treatment: F4.77,1 23.98 = .86, p = .51; 
intensity by genotype by treatment F4.77,1 23.98 = .52, p = .75). Consequently, PPI 
intensity was pooled into total PPI scores. Figure 2.1 displays the total PPI 
scores. MDMA failed to significantly disrupt PPI F2,52 = .48, p = .62, and this 
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pattern was consistent across  genotype, F1,52 = .00, p = .99. Additionally, no 
interaction was found F2,52 = 1.36, p = .27.  
 
Figure 2.1.  Percentage inhibition for SERT+/+ and SERT-/- animals injected with saline (0 mg/kg), 
5 mg / kg or 10 mg / kg MDMA i.p. Values were obtained by dividing pre-pulse inhibition scores 
by the mean of the startle trials. n = 7 – 8 per MDMA group, n = 14 -16 per saline group. Bars 
represent the mean (+SEM). 
 
Figure 2.2 displays the percentage change in basal habituation between 
the first and the second block of startle stimuli. A significant effect of genotype, 
F1,52 = 10.42, p = .002, and dose, F2,52 = 4.12, p = .02, was found, as well as a 
significant interaction, F2,52 = 5.12, p = .01. This effect was driven by a significant 
difference in SERT+/+ rats, F2,25 = 4.75, p = .02. Follow up tests indicate that for 
SERT+/+ animals there was a significant decrease in startle habituation from the 
first to the second startle stimulus blocks following 5 mg / kg MDMA, but not 10 
mg / kg, compared to saline (p = .02), suggesting MDMA disrupts normal startle 
habituation. For SERT-/- animals however, there was no significant effect of 
MDMA dose on habituation to the startle stimuli, F2,27 = .19, p = .83, indicating 
that MDMA does not affect startle habituation in animals lacking the SERT. 
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Figure 2.2. Percentage change in habituation between the first and second blocks of startle 
stimuli for SERT -/- and SERT +/+ animals injected with saline (0 mg / kg), 5 mg / kg or 10 mg / kg 
MDMA i.p. Negative values denote decreased mean startle response to startle stimuli from the 
first to second blocks. n = 7 – 8 per MDMA group, n = 14 -16 per saline group. Bars represent the 
mean (+SEM). * p < .05. 
 
 
Locomotor Activity 
Baseline activity. As expected, baseline ambulatory counts between 
animals that would be receiving saline or drug within each genotype did not 
differ (SERT+/+: t12 = .1, p = .92; SERT-/-: t12 = -2.03, p = .07). Consequently, 
genotypes were pooled for analysis (Figure 2.3a). Pooled analysis revealed a 
significant difference between genotype, t26 = -3.15, p = .01, with an increase in 
baseline ambulation for SERT-/- rats. 
 
Figure 2.3. A) Baseline ambulatory counts in the open field for both SERT +/+ and SERT -/- animals; 
and B) Baseline stereotyped behaviour in the open field for both SERT +/+ and SERT -/- animals. N 
= 7 – 8 per group. Bars represent the mean (+SEM). *p < .05  
 36 
 
 Additionally, baseline stereotypy counts between animals that would be 
receiving saline or drug within each genotype did not differ either (SERT+/+: t12 
= -.03, p = .98; SERT-/-: t13 = -1.22, p = .25), and so genotypes were also pooled 
for analysis (Figure 2.3b). These analyses indicated no genotype differences 
were present, t27 = -.76, p = .46. 
Acute MDMA. Figure 2.4a shows the locomotor response to acute 2.5 mg 
/ kg MDMA or saline (0.0 mg / kg MDMA). MDMA increased locomotor activity 
in both genotypes, F1,25 = 8.06,  p = .01, however, although this effect appears to 
be diminished in SERT-/- rats, no effect of genotype was present, F1,25 = .16,  p = 
.69, and no significant interaction was observed, F1,25 = .70,  p = .41.  
Acute MDMA also increased stereotyped behaviour, Figure 2.4c, F1,25 = 
13.60,  p < .001, and a difference between genotypes was also observed, F1,25 = 
5.86,  p = .02, though no interaction was found F1,25 = 1.26,  p = .27 (Figure 2.4b). 
Follow-up tests indicate there was a tendency for the SERT+/+ animals to show 
more stereotypy following acute MDMA compared to SERT-/- rats, t8.34, = 2.04, p 
= .07. 
Repeated MDMA. Figure 2.4b shows the number of ambulatory counts 
following repeated exposure to MDMA. MDMA (2.5 mg / kg) increased 
locomotor activity in both genotypes, F1,25 = 10.38,  p < .001, however the 
amount of locomotor activity did not differ between genotypes, F1,25 = .00, p = 
.95, and no significant interaction was observed, F1,25 = .09,  p = .76. Neither 
genotype exhibited sensitisation to MDMA following repeated exposure to 
MDMA, if anything, ambulation was decreased following repeated MDMA, 
although this was not significant (SERT+/+ animals, t6 =1.53, p = .18; SERT-/- 
animals t6 = 1.33, p = .23).  
Figure 2.4d shows stereotypy following repeated MDMA.  An effect of 
treatment was found, F1,25 = 13.06,  p < .001, however, the amount of stereotypy 
did not differ between genotypes, F1,25 = 1.15,  p = .29. No significant interaction 
was observed, F1,25 = .38,  p = .54. Neither genotype exhibited sensitisation of 
stereotyped behaviour to MDMA following repeated exposure to MDMA 
(SERT+/+, t6 = 1.5, p = .18; SERT-/- , t6 = 1.33, p = .23). 
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Figure 2.4. A) Ambulatory counts for SERT +/+ and SERT -/- animals following an acute injection 
of 2.5 mg / kg MDMA or saline  (0.0 mg / kg MDMA) i.p. within the open field; C) Stereotypy counts 
for SERT +/+ and SERT -/- animals following an acute injection of 2.5 mg / kg MDMA or saline (0.0 
mg / kg MDMA) i.p. within the open field. N = 7 - 8 per group; B) Ambulatory counts for SERT +/+ 
and SERT -/- animals following an acute injection of 2.5 mg / kg MDMA or saline (0.0 mg / kg 
MDMA) i.p. following exposure to MDMA  each day or 5 days followed by a 2 day withdrawal; C) 
Stereotypic counts for SERT +/+ and SERT -/- animals following an acute injection of 2.5 mg / kg 
MDMA or saline (0.0 mg / kg MDM A) i.p. following repeated exposure to MDMA. N = 7 - 8 per 
group. Bars represent the mean (+SEM). *p < .05. 
 
Drug Discrimination 
Figure 2.5a shows the cumulative percentage of animals that met the 
discrimination criterion. Although the majority of SERT+/+ rats (70%) learnt to 
discriminate saline and MDMA, only around 30% of SERT-/- did. A Kaplan–Meier 
survival analysis showed a significant leftward and upward shift in the curve of 
the SERT+/+ group compared with the SERT-/- group, χ21 = 9.41, p = .02. These 
results indicate that the discriminative stimulus properties of MDMA were 
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significantly lowered in SERT-/- compared with SERT+/+ rats. As displayed in 
figure 2.5b, there were no differences between genotypes for response rate, 
t7.15, .54, p = .60. 
 
 
Figure 2.5. A) Cumulative percentage of SERT-/- (n = 7) and SERT+/+ (n = 7) rats that met 
discrimination criterion as a function of test session. B) Overall mean response rate (responses 
per second) to complete the first fixed ratio 10 during the final ten discrimination sessions, for 
both SERT-/- (n = 6) and SERT+/+ (n = 7) rats. Bars represent the mean (+SEM). *p < .05. 
 
 
 
Figure 2.6. Mean number of responses of SERT-/- (n = 5) and SERT+/+ (n = 3) rats on either the 
saline- or MDMA-appropriate lever following a 0.5 mg / kg amphetamine i.p probe. Bars represent 
the mean (+SEM). *p < .05. 
 
Only five SERT+/+ rats, and three SERT-/- rats met the discrimination 
criterion and moved on to probe generalisation with 0.5 mg / kg amphetamine 
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(Figure 2.6). SERT+/+ animals showed partial stimulus generalisation to MDMA, 
with an average of 40% responses on the MDMA-appropriate lever, while SERT-
/- animals responded almost exclusively on the amphetamine-appropriate lever. 
This resulted in a significant lever by genotype interaction, F1,6 = 6.09, p = .049,  
but no effect of lever, F1,6 = 2.98, p = .14, or genotype, F1,6 = .56, p = .48. Follow 
up t-tests indicated that no differences existed between lever choice for SERT+/+ 
animals, t4 = -.50, p = .65, while a significant difference was found for SERT-/- 
rats, t2 = 32.13, p < .01.  
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Discussion 
Pre-pulse inhibition and startle habituation 
 MDMA-induced disruption of startle habituation was abolished in SERT-/- 
rats, indicating that the SERT is necessary for the disruption of MDMA to startle 
habituation. These results are in line with previous pharmacological studies 
(Kehne et al., 1992). While no difference was observed between genotypes in 
MDMA-induced disruption of PPI, given that MDMA failed to disrupt PPI in the 
control SERT+/+ group, it is impossible to establish whether genetic abolition of 
the SERT affects MDMA’s effect on sensorimotor gating. A possible explanation 
for the lack of disruption in control rats is that a relatively modest range of 
MDMA was used (5 and 10 mg / kg MDMA). This range was deliberately 
selected to prevent any possible ceiling or floor effects (upper or lower limits 
for which any differences between groups for a dependant variable can no 
longer be discerned). However, previous studies used the higher dose of 20 mg 
/ kg MDMA (Padich et al., 1996), indicating that very high doses of MDMA may 
be required to disrupt PPI. Nevertheless, pilot testing of this dose led to 
mortality in SERT-/-, rats, and so this dose was not continued for animal welfare 
reasons.  
Although the doses selected may have been too low to affect PPI, 5 mg / 
kg MDMA did abolish habituation to a startle stimulus in the SERT+/+ rats, but 
not SERT-/- rats. Given that previous studies have demonstrated disruption of 
startle habituation with 20 mg / kg MDMA (Kehne et al., 1992), it is strange that 
disruption was not observed in control rats following 10 mg / kg MDMA. This is 
likely due to the effects of sustained habituation between sessions. Ideally, the 
two MDMA doses would have been counter balanced in order to prevent order 
effects. However, 5 mg / kg MDMA was initially the sole dose employed. Given 
its lack of efficacy in significantly disrupting PPI in SERT+/+ rats, the experiment 
was repeated using 10 mg / kg MDMA. In order to minimise drug effects, 10 mg 
/ kg MDMA was given to those rats which had previously been administered 
saline (and vice versa). While a 1 week washout period was given between 
sessions, the disruption of startle habituation by MDMA was diminished in the 
10mg / kg group. Habituation to a startle stimulus has previously been shown 
to be sustained for up to 7 days (Moyer, 1963), so it is possible habituation was 
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sustained in these animals. However, there was no significant difference in 
habituation across the two saline groups, one of which was not naive to the 
paradigm so this conclusion is tentative. As noted above, pilot testing with 20 
mg / kg MDMA was unsuccessful; however 10 mg / kg MDMA should be 
repeated in paradigm naïve animals in order to determine whether the effect of 
10mg / kg MDMA on startle habituation is really diminished in these animals. 
Indeed, subsequent data collected in our laboratory group has shown the same 
effect of MDMA-induced disruption of startle habituation in experimentally 
naïve SERT+/+ rats with 10 mg / kg MDMA. 
It should be noted that, unlike previous studies that employed a discrete 
startle trial, the startle trials in the current experiment were given within a 
session that included PPI trials (Kehne et al., 1992; Stevenson & Gratton, 2004). 
Consequently, instead of measuring habituation across the whole session, 
habituation was measured as the percentage change in basal habituation 
between two blocks of 5 startle stimuli. While this paradigm fails to account for 
possible sensitisation within the first block (Halberstadt & Geyer, 2009) this is 
unlikely to be of great concern given the significant results found between 
genotypes. If anything, it is possible the effect was underestimated. Retesting 
the effects of MDMA in a pure startle habituation session (i.e. a session where 
only startle stimuli are presented) would help elucidate this. 
Locomotor activity  
Disruption of forward locomotion and stereotypy by MDMA was found to 
be largely unaltered in SERT-/- rats, although the effects of MDMA did appear to 
be slightly diminished in SERT-/- rats. These findings indicate the SERT may not 
be necessary for the locomotor activating effects of MDMA, and are in spite of 
previous pharmacological studies indicating that MDMA-induced locomotor 
activity is mediated by 5-HT, as well as DA (Daniela et al., 2004; Kehne et al., 
1996). However, SERT-/- rats did display an increase in baseline forward 
locomotion, indicating that 5-HT may mediate locomotion in response to 
novelty. Finally, sensitisation to the locomotor effects of MDMA following 
repeated exposure was not observed in either genotype, and so it is impossible 
to determine whether abolition of the SERT alters MDMA sensitisation. 
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It is possible the different conclusions regarding the role of 5-HT in the 
locomotor activating effects of acute MDMA between the current study and 
previous pharmacological studies are mediated by the lack of specificity within 
these pharmacological agents. More importantly, findings published following 
the completion of the current study indicate that MDMA-induced increases in 
velocity were diminished in SERT-/- rats (Lizarraga et al., 2014). It is possible 
that MDMA-induced decreases in hyperactivity in SERT-/- rats are only present 
at higher doses of MDMA given that Lizarraga et al. (2014) used 10mg / kg 
MDMA (compared with 2.5 mg / kg in the current study). However, there are 
methodological issues that limit any such conclusions. First, while locomotor 
activity is usually measured as ambulatory counts or distance travelled, 
Lizarraga et al. (2014) used the less often used velocity (cm per minute) 
measurement, and so it is unclear what a decrease in MDMA-induced speed 
implies. Second, Lizarraga et al. (2014) treated all groups as one variable 
(treatment group) as opposed to considering genotype and drug treatment 
separately, which violates the assumption of an ANOVA that groups are 
independent. Consequently, future studies ought to replicate the current 
experiment using higher doses of MDMA to indicate whether the SERT is 
necessary for the locomotor activating effects of MDMA.  
Stereotypy following acute MDMA was similarly increased in both 
genotypes, although there was a trend for this increase to be greater in SERT+/+ 
compared with SERT-/-. While the increase in stereotypy in SERT+/+ rats is in 
keeping with previous findings that MDMA leads to 5-HT syndrome (Baumann 
et al., 2005; Spanos & Yamamoto, 1989), it is surprising there is an increase in 
stereotypic counts in SERT-/- rats, given that MDMA cannot increase 5-HT in 
these rats. It is possible that the method of measuring stereotypy in the present 
study was not ideal. Although stereotypy counts within the open field paradigm 
have previously been found to comprise head weaving and forepaw treading, 
markers of 5-HT syndrome (Baumann et al., 2005), these behaviours were not 
measured directly in the currently study. Moreover, increases in DA have been 
previously correlated with increases in stereotypy within the open field 
(Baumann et al., 2008), and cocaine and amphetamine also increase stereotypy 
counts without inducing clear head weaving or forepaw treading (Kuczenski, 
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Segal, & Aizenstein, 1991). Consequently, it is likely the stereotypy measured in 
this particular paradigm may have been influenced by increases in DA.  
SERT-/- rats did demonstrate increased baseline forward locomotion, but 
not stereotypy, compared with SERT+/+ rats, indicating SERT-/- show enhanced 
activity in their response to novelty. While previous studies with the SERT-/- 
rats have not found any increase in forward locomotion following exposure to 
novel environments (Homberg et al., 2008; Olivier et al., 2008), unpublished 
results from our lab have replicated this effect, indicating this finding warrants 
further investigation. It is surprising that baseline stereotypic behaviour failed 
to differ across genotypes, given that SERT-/- rats have 9-fold increased 5-HT, 
and MDMA-induced stereotypy is thought to be 5-HT mediated. However, as 
mentioned above, it is possible the particular paradigm used to measure 
stereotypy is sensitive to increases in DA. Moreover there is compensatory 
down-regulation in 5-HT receptors that may prevent changes in baseline 
behaviour (Baumann et al., 2008; Homberg et al., 2008). 
Following repeated MDMA, the psychomotor response to MDMA was 
unaltered in both SERT+/+ and SERT-/- rats, indicating that sensitisation to the 
locomotor activating effects of MDMA was not observed in either genotype. 
Consequently, it is impossible to determine whether any differences exist in 
MDMA sensitisation following the ablation of the SERT. It is likely the dose used 
in the current study was too low to produce sensitisation. Indeed, previous 
studies that have demonstrated sensitisation following repeated MDMA have 
used much higher doses than those used in the current study (5 and 10 mg / kg 
(Colussi-Mas & Schenk, 2008; Ramos et al., 2004)). The dose of 2.5 mg / kg was 
chosen for the current study as it is both behaviourally active but not so high so 
as to produce a ceiling effect whereby no effect of genotype could be elucidated. 
However, as no effect of sensitisation was observed in the control SERT+/+ rats, 
it would be useful to assess multiple doses of MDMA within this paradigm. 
Drug discrimination  
While only a small number of SERT-/- rats managed to discriminate low dose 
MDMA from saline in the learning phase of the task, those that could were 
unable to differentiate amphetamine from low dose MDMA. MDMA 
preferentially increases extracellular 5-HT and has a relatively diminished effect 
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on extracellular DA in normal animals (Baumann et al., 2008; Han & Gu, 2006). 
Thus, whereas, in line with previous studies, amphetamine only partially 
generalised to MDMA in animals with a functional SERT (Kueh & Baker, 2007; 
Oberlender & Nichols, 1988), it fully substituted for MDMA in SERT-/- rats. 
These findings support previous assertions that 5-HT plays a crucial role in the 
discriminative stimulus effects of low dose MDMA (Harper et al., 2014). 
Moreover, it is well established that the discriminative stimulus properties of 
amphetamine are almost exclusively mediated via DA (Callahan, Appel, & 
Cunningham, 1991). The data therefore suggest that in the SERT-/- rats the 
discriminative stimulus properties of MDMA are also mediated via DA. 
Consequently, it is possible that when administered to SERT-/- rats, MDMA 
shares the well-established greater abuse potential seen with self-
administration of amphetamine. Indeed, this hypothesis is tested in Chapter 3.  
The differential effect on the SERT and the DAT likely explains the low 
number of SERT-/- rats that learned to discriminate low dose MDMA from saline. 
As MDMA cannot act upon the SERT in the SERT-/- rats, it is likely that the very 
small dopaminergic effect seen with this dose of MDMA was not strong enough 
to allow the SERT-/- rats to reliably differentiate MDMA from saline. While it is 
likely learning would increase if training occurred with a high dose of MDMA, 
such as 3 mg / kg, this dose would produce an increase in the DA effect of 
MDMA, and may therefore mask any existing differences between genotypes. 
 
Although genetic reductions in SERT function found in humans do not 
lead to a complete ablation of the SERT, as seen in the SERT-/- rats, in humans, 
polymorphisms have been reported in the promoter region of the SERT. Some of 
these polymorphisms (most notably the short (s-) allele of the SERT linked 
polymorphic region or 5-HTTLPR) lead to a significant reduction in SERT 
function (Lesch et al., 1996). The findings of the current study back up evidence 
in humans that genetically reduced SERT function leads to alterations in their 
response to MDMA. Although this has not been studied in great detail, there are 
indications that s-allele carriers are more sensitive to some of the behavioural 
effects of ecstasy, such as deficits in attention and decision making (Cuyàs et al., 
2011; Roiser et al., 2005; Roiser et al., 2006), as well as increased occurrences of 
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mood disorders (Martín-Santos et al., 2010). Furthermore, the results of the 
drug discrimination study indicate these individuals may subjectively 
experience MDMA as being more amphetamine-like than individuals who do not 
have this genetic variation.  
 
 
Conclusion 
The current results indicate that genetic removal of the SERT results in 
an alteration in the behavioural effects of MDMA. While this genetic removal 
resulted in an abolishment of MDMA-induced disruption to startle habituation, 
it failed to affect MDMA-induced increases in locomotor activity, implying that 
the SERT is necessary for MDMA’s disruption of startle habituation but not its 
psychomotor effects. Moreover, for those rats that could discriminate low dose 
MDMA from saline, genetic removal of the SERT resulted in a removal of the 
ability to partially discriminate MDMA from amphetamine, supporting the 
notion that 5-HT plays a crucial role in the discriminative stimulus effects of a 
low dose of MDMA. Moreover, these findings imply that, in these rats, MDMA 
was now subjectively indistinguishable from amphetamine. Overall, the current 
findings support studies in humans that indicate individuals with genetically 
reduced SERT functions display an altered response to MDMA under certain 
conditions.   
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Chapter 3: A genetic deletion of the serotonin transporter greatly 
enhances the reinforcing properties of MDMA in rats 
This chapter was adapted from Oakly, Brox, Schenk, and Ellenbroek (2014). 
Many drugs of abuse preferentially increase synaptic dopamine (DA) but 
also exert effects on other brain systems that might either enhance or limit 
subsequent rewarding effects and abuse liability. For example, serotonin (5-HT) 
is inhibitory to DA signalling (Baumann et al., 2011). Therefore, the ability of 
many drugs of abuse to also enhance 5-HT might limit reward-mediated self-
administration (Hayes & Greenshaw, 2011). Accordingly, variations in drug-
produced DA and/or 5-HT release might explain between-subject variability in 
the propensity to self-administer drugs of abuse. (±) 3, 4-
methylenedioxymethamphetamine (MDMA) is an excellent candidate to test 
this hypothesis because, while many other drugs of abuse, such as cocaine and 
amphetamine, preferentially enhance extracellular levels of DA (by blocking or 
reversing the DA transporter or DAT), MDMA preferentially binds to the 
serotonin transporter (SERT) thereby enhancing extracellular 5-HT levels to a 
greater extent than DA (Cole & Sumnall, 2003; Han & Gu, 2006). This 
pharmacological effect would be expected to limit the rewarding effects of 
MDMA because manipulations that increase extracellular 5-HT, such as selective 
5-HT reuptake inhibitors (SSRI), are not positively reinforcing and have been 
found to reduce the rewarding properties of other psychostimulant drugs 
(Baumann et al., 2011; Carroll et al., 1990a). Indeed, although the abuse liability 
of MDMA is now well established, it is lower than that of most other drugs of 
abuse. This is evident both in humans and rats with only a relatively small 
proportion of MDMA users progressing to dependence (Degenhardt, Bruno, & 
Topp, 2010) and only ~50% of Sprague-Dawley rats developing reliable MDMA 
self-administration (Schenk, Colussi-Mas, Do, & Bird, 2012). 
In the present study, we tested the hypothesis that MDMA’s acute effects 
on the SERT underlie its reduced abuse liability by measuring MDMA self-
administration in rats with a genetic deletion of the SERT. Although these 
animals have a 9-fold higher tonic synaptic (extracellular) level of 5-HT, drug 
effects mediated by the SERT are absent (Homberg et al., 2007). This animal 
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therefore provides a unique opportunity to establish whether the binding of 
MDMA to the SERT and the subsequent change in extracellular 5-HT is an 
important factor in the development and maintenance of MDMA self-
administration. 
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Method 
Subjects   
Serotonin transporter knockout rats (SLC6A41Hubr, SERT-/-) were 
originally created via N-ethyl-N-nitrosourea (ENU)-induced mutagenesis in a 
commercial (Harlan, Ter Horst, The Netherlands) wild-type Wistar rat (Smits et 
al., 2006). Experimental animals were generated by breeding pairs of SERT-/- or 
wild-type (SERT+/+) animals who had been bred by crossing heterozygous 
animals (SERT+/-) that had been outcrossed for at least 6 generations. Parent 
animals had been previously genotyped at 3 weeks of age. Ear samples were 
taken and used for genotyping (performed at Transnetyx, Cordova, USA). 
Twenty four experimentally naïve adult male rats (13 SERT-/-, 11 SERT+/+) 
weighing 300 - 400 g were used for self-administration. Female rats were not 
used in the current set of experiments due to unpublished findings from our lab 
that indicate self-administered MDMA significantly increased mortality in 
female rats. Animals were bred and reared at the vivarium of the School of 
Psychology at Victoria University of Wellington. Animals were housed in groups 
of three to six until they reached 300 - 400 g (approximately 90 days), at which 
point they were housed individually in hanging polycarbonate cages in a 
temperature (19 - 21 oC) and humidity (55%) controlled room. Animals were 
kept on a normal 12 hr light/dark cycle (lights on from 07.00 – 19.00 h), with 
testing being conducted during the light phase. Aside from testing hours, water 
and food were available ad libitum. All protocols were approved by the Victoria 
University of Wellington Animal Ethics Committee (AEC-2012R2). 
 
Apparatus and procedure  
Surgery. Surgery protocols were identical to those used in Schenk, 
Harper, and Do (2011). One week prior to self-administration, rats were 
surgically implanted with a chronic indwelling catheter, while under deep 
anaesthesia produced by intraperitoneal (i.p.) injections of a ketamine (90.0 mg 
/ kg; Phoenix Pharm Distributors LTD, New Zealand) and xylazine (9.0 mg / kg; 
Phoenix Pharm Distributors LTD, New Zealand) mix. Post anaesthesia, lubricant 
eye ointment was applied across the cornea of the eye to prevent excessive 
dryness and Carprofen (5.0 mg / kg, subcutaneous (s.c.); Norbrook NZ LTD, New 
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Zealand) was administered for pain. Fur on the skull and chest was shaved, and 
an iodine-ethanol mix was applied. A small incision was made in the chest and 
the right external jugular vein was isolated and tied off with an ethanol soaked 
polyamide thread. A silastic catheter (cured tubing coated in silicone, fitted to a 
2 cm length of 22 gauge stainless steel cannula) was passed subcutaneously 
from an exposed portion of the skull to the chest. A small cut was then made 
into the jugular vein into which the catheter was inserted and tied off. The 
incision was closed with super glue, and topical antibiotic (Terramycin powder; 
Pfizer Animal Health, Australia) was applied. The catheter was secured to the 
skull using dental acrylic adhered to 4 small stainless steel jeweller’s screws 
(Centrostyle, Italy, Ref.00395) embedded in the skull. Additionally, the head of a 
6-32 x 3/8 counter sunk stainless steel screw was adhered to the dental acrylic 
for the purpose of attaching the rat to the spring encasement in the operant 
chamber. Topical antibiotic was also applied to the skull incision. To prevent 
dehydration and aid recovery, 5mL of a compound sodium lactate solution 
(Hartmann’s solution) was injected subcutaneously on each side of the rat (10 
mL total). Testing began following a 7 day recovery period. For 2 days following 
surgery, rats were given Carprofen (5.0 mg / kg, s.c.) for pain. Each day 
following surgery catheters were infused with 0.2 ml sterilised 0.9% saline 
solution, containing heparin (3.0 I U / mL) and penicillin G potassium (250 000 I 
U / mL), to maintain catheter patency, and to prevent infection and the 
formation of clots and fibroids. The day immediately prior to testing, and every 
seven days thereafter, catheter patency was confirmed: Catheters were infused 
with 0.1 mL of heparin-penicillin solution, and then 0.04 mL was drawn up. If 
blood was successfully drawn the catheter was deemed functional. If not, it was 
infused with 0.15 mL of sodium pentobarbital (5.0 mg / kg, intravenous (i.v.)). 
Loss of righting reflex confirmed catheter patency. Rats were maintained in 
their home cages in the animal facility until testing.  
 Apparatus. Self-administration tests were conducted in 28 x 21 x 21 cm 
operant conditioning chambers (ENV-001, Med Associates Inc., Vermont) 
equipped with two levers. Depression of one lever (the ‘active’ lever) resulted in 
a 12.0-s intravenous infusion (0.1 mL) of MDMA, as well as the illumination of a 
stimulus light above the lever. Depression of the other lever (the ‘inactive’ lever) 
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was without programmed consequence, but was recorded. Infusions were 
delivered via a mechanical pump (Razel, Model A with 1 rpm motor), which 
housed a 20 mL syringe, by which drug was delivered i.v. via silastic tubing. 
Tubing entered the chamber from above via a swivel (Harvard Apparatus, USA), 
which allowed for free movement by the animal in the chamber. Drug delivery 
and data acquisition were controlled by an interfaced microcomputer using a 
commercially available software package (Med-PC IV, Med Associates Inc., 
Vermont). The testing room was temperature (19 - 21 oC) and humidity (55%) 
controlled. 
Procedure. Testing was conducted during daily 2-h sessions which took 
place between 12:00 and 17:00 from Monday–Saturday. Both immediately prior 
to, and following, each daily test session, the catheters were infused with 0.2 mL 
of the heparin-penicillin solution. Rats were then placed in the operant 
conditioning chambers, and the exposed stainless steel tubing was attached to a 
length of silastic tubing through which drug was delivered.  
Acquisition of MDMA self-administration. 13 SERT-/- along with 11 
SERT+/+ animals were used. Every session began with an experimenter 
delivered infusion of drug. Thereafter, each depression of the active lever (fixed 
ratio 1 reinforcement schedule) resulted in an automatic infusion of MDMA (1.0 
mg ⁄ kg per infusion) paired with the illumination of a stimulus light located 
directly above the active lever. Pressing the incorrect lever was recorded but 
had no consequences. The criterion for acquisition was the same as that used 
previously in our lab (Schenk et al., 2012), rats were considered to have 
acquired self-administration if they obtained 90 infusions of MDMA within 25 
days.  
Maintenance of MDMA responding. Upon acquisition, rats (13 SERT-/- 
and 6 SERT+/+) received additional tests to examine further the dose dependent 
nature of responding maintained by MDMA. Once animals obtained 90 
infusions, the dose was halved to 0.5 mg / kg per infusion. Following stable 
responding on this dose (approximately 4 days), the reinforcement schedule 
was increased to fixed ratio 2, and then fixed ratio 5.  
Progressive ratio responding. Remaining rats (10 SERT-/- and 6 
SERT+/+ rats) were subsequently tested under conditions of a progressive ratio 
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of reinforcement. For these tests, the ratio requirements increased 
logarithmically during each daily test as described previously (Richardson & 
Roberts, 1996). The session was terminated when the rat failed to gain an 
infusion following a 60-min period. The breakpoint and number of infusions 
earned were determined under this schedule, with breakpoint defined as the 
last ratio successfully completed. The 3 doses of MDMA used (0.25, 0.5 and 1.0 
mg / kg per infusion) were assigned in pseudorandom order and given with one 
standard fixed ratio 5 session in between each dose. 
Extinction and reinstatement of MDMA seeking behaviour. 
Following progressive ratio testing, one standard fixed ratio 5 session was 
completed, after which drug seeking following abstinence was investigated (10 
SERT-/- and 4 SERT+/+ rats). During extinction, when the active lever was 
depressed, the stimulus light remained off and rats received an infusion of 
vehicle on an fixed ratio 5 reinforcement schedule. Once rats had reached a 
criterion of extinction (fewer than 20% of their average responses per session 
on the active lever) they were then reinstated with an i.p. injection of 10 mg / kg 
MDMA 10 minutes prior to commencement of the session, with the stimulus 
light turned back on, as previously used in our lab (Schenk, Gittings, & Colussi-
Mas, 2011). 
 
Drugs 
MDMA HCl was obtained from Environmental Science and Research 
(Porirua, New Zealand). MDMA was dissolved in a sterile solution of 
heparinised (3 I U ⁄ mL) physiological saline. All weights refer to the anhydrous 
salt and not the acid. 
 
Data Analysis 
 Acquisition of self-administration was compared between genotypes 
using the log-rank test to compare Kaplan-Meier survival estimates. Right-
censoring was applied to rats that did not acquire within 25 days. Time-course 
data were converted into the number of responses that occurred in the first 30 
minutes of the 2-hour session as a proportion of the total number of responses. 
This was in order to determine whether subjects were loading their responses 
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at the beginning of the session, a pattern typically found in MDMA self-
administration (Schenk et al., 2003). The data for the first three experiment 
days, time-course, maintenance and progressive ratio were analysed using a 
repeated measures analysis of variance (ANOVA), with either experiment day / 
fixed ratio / dose entered in as a within subjects factors, and genotype entered 
as a between subjects factor. The Greenhouse-Geisser correction was used 
whenever sphericity was violated. Post-hoc analyses, where appropriate, were 
conducted using independent samples t-tests, with equal variances not assumed 
if Levene’s test for equality of variances was significant. Extinction and 
reinstatement were analysed using independent samples t-tests. Extreme 
outliers were identified using SPSS’s outlier tests and removed. The alpha level 
for statistical significance was set at p < .05. All statistical analyses were 
performed using IBM SPSS Statistics version 22 for windows. 
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Results 
Acquisition 
Figure 3.1a displays the average lever responses for 1.0 mg / kg MDMA 
over the initial 3 days of the experiment. Only the first 3 days of the experiment 
were considered in the initial analysis as this was prior to any subject meeting 
the acquisition criterion, as this event resulted in a change in MDMA dose and 
subsequent change in responding. While no main effect of experimental session 
was found, F1.22, 28.04 = 1.13, p = .31, there was a moderately significant effect of 
genotype, F1, 23 = 4.11, p = .05, as well as a significant interaction, F1.22, 28.04 = 4.1, 
p = .045. Post-hoc comparisons revealed that, while there was no significant 
difference between groups on day 1, t23 = .15, p = .88, there was a trend towards 
a significant difference on day 2, t14.48 = 2.04, p = .06, and a significant difference 
on day 3, t13.06 = 2.31, p = .04, indicating that, while both genotypes performed 
similarly upon experiment commencement, SERT-/- animals progressively 
responded more as the experiment continued. 
 
 
Figure 3.1. A) Average responses on the active lever (+SEM) for SERT +/+ (n  = 11) and SERT -/- (n 
= 13) during the first 3 days of self-administration of 1.0 mg / kg MDMA; and B) Survival curves 
for the acquisition of MDMA self-administration for SERT-/- and +/+ rats. *p < .05. 
 
In order to establish whether SERT-/- animals acquired self-
administration behaviour significantly more than SERT+/+ animals, an 
acquisition criterion previously established in our lab  (more than 90 presses on 
the active lever within 25 days; (Schenk et al., 2012) was applied to all animals. 
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Within 25 days, all 13 SERT-/- rats (100%) acquired self-administration 
behaviour, compared with only 6 of 11 (55%) SERT+/+ animals.  A log rank test 
was run to determine if there were differences in the survival distribution 
between the SERT-/- and SERT+/+ rats. Figure 3.1b shows the survival curves for 
the acquisition of self-administration, with SERT-/- rats displaying a significant 
increase in the probability of acquiring MDMA self-administration over the time 
period considered, χ21 = 9.41, p < .001. This suggests that the reinforcing 
properties of MDMA were stronger in the SERT-/- rats compared to the SERT+/+ 
animals. 
 
Figure 3.2. Average proportion of responding occurring in the first 30 minutes of the 2 hours 
session for both the last 3 days prior to acquisition (1.0 mg / kg MDMA), and the first 3 days after 
acquisition (0.5 mg / kg MDMA) for both SERT-/- (n = 13) and SERT+/+ (n = 11) rats. Bars represent 
mean (+SEM). *p < .05. 
 
Figure 3.2 displays the proportion of responding occurring in the first 30 
minutes both prior to, and following acquisition. All subjects appear to perform 
a majority of their responses within the first 30 minutes, as has been found 
previously (Schenk et al., 2003). Statistical analyses found no effect of 
experimental day, F1, 17 = 1.25 p = .28, and no effect of genotype, F1, 17 = 34.54, p 
= .87. This indicates there are no differences between SERT-/- and SERT+/+ rats 
in the pattern of responding. 
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Maintenance  
An enhanced susceptibility of the SERT-/- rats to MDMA was also 
apparent during maintenance (Figure 3.3) with statistical analysis showing a 
significant main effect of fixed ratio , F1.32, 22.38 = 34.54, p < .001, and genotype, 
F1, 17 = 5.73, p = .03, but no interaction, F1.32, 22.38 = 2.20, p = .15. Follow up post-
hoc tests revealed that SERT-/- animals infused significantly more MDMA than 
SERT+/+ animals with a fixed ratio  of 1, t17 = 2.33, p = .03, as well as when the 
fixed ratio  was increased to 2, t17 = 2.55, p = .02. However, when the fixed ratio  
was increased to 5, the increase in responding by SERT-/- was only marginally 
significant, t17 = 1.98, p = .05. 
 
 
Figure 3.3. Responding maintained by a fixed ratio  of 1, 2 or 5 with 0.5 mg / kg MDMA for SERT 
-/- (n = 13) and SERT +/+ (n = 6) animals. Bars represent mean number of active lever responses 
(+SEM) during daily 2-hour sessions. *p < .05. 
 
Progressive ratio 
Means are displayed in Figure 3.4a. A dose by genotype interaction was 
found, F2, 22 = 4.83, p = .02.  However no main effect of dose F2, 22 = 2.17, p = .14, 
or genotype, F1, 11 = 3.38, p =.09, was observed. While follow up post-hoc tests 
indicate that for 0.25 mg / kg there was no significant difference between 
SERT+/+ and SERT-/- animals, t914 = -.12, p = .91, significant differences between 
groups were found for the higher doses: 0.5 mg / kg: t9.03 = 2.87, p = .02; and 1.0 
mg / kg: t11.18 = 2.61, p = .03. This suggests that SERT-/- animals will work harder 
for higher doses of MDMA compared with SERT+/+ animals. 
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Figure 3.4.  Mean number of infusions earned (A) or break point (B) as a function of MDMA dose 
for SERT -/- (n=10) and SERT +/+ (n= 6) animals during progressive ratio tests of self-
administration. Bars represent the mean (+SEM). *p < .05. 
 
Extinction and reinstatement 
There was no significant difference in the time to extinguish drug 
seeking behaviour between SERT+/+, figure 3.5a, t13 = -.32, p = .75.  Following 
extinction, animals were reinstated with a dose of 10mg / kg MDMA plus light 
cue. However, there was no effect of genotype on reinstatement, figure 3.5b, t12 
= .43, p = .67.  
 
 
Figure 3.5.  A) Mean number of days to extinguish lever pressing behaviour following MDMA self-
administration paradigm for SERT-/- (n=10) and SERT +/+ (n= 5) animals; B) Mean number of lever 
presses following reinstatement of MDMA self-administration with 10mg / kg MDMA plus light 
cue for SERT-/- (n=10) and SERT +/+ (n= 4). Bars represent the mean (+SEM). 
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Discussion 
These data show that SERT-/- rats are more sensitive to both the initial 
and subsequent reinforcing properties of MDMA. This is remarkably similar to 
previous findings from our lab that showed animals with reduced 5-HT 
neurotransmission following selective lesions of 5-HT neurons by the 
neurotoxin 5,7-dihydroxytryptamine display enhanced acquisition of MDMA 
self-administration (Bradbury et al., 2013). Moreover, this pattern is consistent 
with the findings of studies using other psychostimulants such as cocaine and 
amphetamine (Leccese & Lyness, 1984; Pelloux et al., 2012). Interestingly, while 
the lesioned animals and the SERT-/- rats share their lack of the SERT, SERT-/- 
rats have 9-fold increased basal level of extracellular 5-HT (Homberg et al., 
2007), while the lesioned animals have significantly reduced basal 5-HT levels. 
This strongly suggests that, rather than the basal (tonic) level, it is the drug-
induced phasic increase in extracellular 5-HT which limits the reinforcing 
properties of MDMA (and by analogy of other psychostimulants such as 
cocaine). 
Although so far, the distinction between tonic and phasic 5-HT release 
has not received much attention, it has played a major role in our understanding 
of the functional role of DA (Grace, 1995, 2000). Given the structural similarities 
between 5-HT and DA implying comparable function, it is possible the 
serotonergic system is similarly regulated. DA regulation is proposed to occur in 
two ways: a fast acting, brief, phasic response; and a slow acting, longer lasting, 
tonic response. The phasic response refers to the high volumes of DA released 
from the pre-synaptic neuron in response to behaviourally relevant stimuli. This 
phasically released DA stimulates postsynaptic DA receptors but is rapidly 
taken back up into the presynaptic neuron by DAT. In the tonic response, DA is 
released by the pre-synaptic neuron in response to excitatory stimulation (e.g. 
by glutamate), at levels too low to be taken back up into the presynaptic neuron 
by DAT. This tonically released DA then diffuses out of the synapse, where it 
acts to homeostatically regulate the dopaminergic system by activating 
presynaptic autoreceptors, which in turn regulates the release of phasic DA 
though various processes including decreased DA cell firing and decreased DA 
synthesis. 
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MDMA primarily exerts its effects both by blocking the SERT and 
inducing reverse transport. This phasic release of 5-HT is then able to diffuse 
into the extrasynaptic space, thereby increasing tonic 5-HT levels. The increased 
tonic 5-HT will then stimulate 5-HT autoreceptors, thereby down regulating the 
serotonergic response, resulting in the dysphoric mood reported in the days 
following MDMA use (Parrott & Lasky, 1998). This process will differ in SERT-/- 
rats due to their complete lack of SERT. As with animals with lesions in the 
serotonergic system, when MDMA is administered to SERT-/- rats it is unable to 
phasically increase 5-HT. MDMA is still able to phasically increase DA in these 
animals however, and so the reinforcing effects of MDMA can be experienced 
without inhibition by 5-HT (Baumann et al., 2011; Rothman & Baumann, 2006), 
thereby increasing the reinforcing efficacy of MDMA in these animals. It is 
therefore likely that the inability of drugs of abuse to induce a phasic 5-HT 
release, rather than a sustained, tonic reduction in 5-HT levels, that enhances 
the reinforcing properties in animals with serotonergic lesions. This suggests 
that reducing the 5-HT levels in adulthood in SERT-/- rats is unlikely to reverse 
the enhanced sensitivity to MDMA.  
The present study is the first to investigate the impact of the SERT on 
MDMA self-administration in genetically modified rats. The impact of this 
deletion is substantial and indicates a much greater role of drug produced 5-HT 
efflux in the acquisition and maintenance of self-administration than was 
previously shown when acquisition of cocaine self-administration was 
measured (Homberg et al., 2008). Accordingly, the data indicate a much more 
significant role of SERT in the reinforcing effects of MDMA than previously 
considered. Indeed, with repeated exposure, MDMA leads to a down-regulation 
of SERT (Schenk et al., 2007) which would explain the eventual acquisition of 
responding by some of the SERT+/+ rats.  Given the important role of DA D1 and 
D2 receptors in MDMA self-administration (Brennan, Carati, Lea, Fitzmaurice, & 
Schenk, 2009), this suggests that SERT-/- rats may have an increased sensitivity 
to dopaminergic stimulation. However, a recent microdialysis study has shown 
that, while cocaine-induced increases in extracellular 5-HT release in the 
nucleus accumbens and hippocampus are smaller in SERT-/- rats than SERT+/+, 
no genotype differences were found for extracellular DA (or norepinephrine 
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(NE)) release (Verheij, Karel, Cools, & Homberg, 2014). Future experiments are 
required to determine whether this finding is consistent across brain structures 
and whether this also holds for MDMA, given its unique pharmacological 
properties. 
Our present set of data from SERT-/- rats are diametrically opposite to 
results obtained from SERT-/- mice. While SERT-/- mice also display anxiety-like 
behaviour (Holmes et al., 2003), as well as increased cocaine-induced 
conditioned place preference (Sora et al., 1998), MDMA self-administration in 
these mice is abolished (Trigo et al., 2007). This difference reinforces the idea 
that the role of 5-HT in the behavioural response to MDMA differs between 
species. Significantly, MDMA produces differential long term effects in mice and 
rats. For instance, MDMA acts as a selective DA neurotoxin in mice, leading to a 
decrease in striatal DA and its metabolites, as well as significantly reducing DAT, 
with minimal effects on 5-HT (Colado et al., 2004; Kindlundh-Högberg et al., 
2007; O'Callaghan & Miller, 1994; O'Shea et al., 2001). Whereas in humans, non-
human primates, and rats there is evidence that long-term use of MDMA leads 
to selective 5-HT depletion and a decrease in SERT expression, increasing the 
addictive potential of MDMA (Buchert et al., 2004; Easton & Marsden, 2006; 
Kindlundh-Högberg et al., 2007; O'Shea et al., 1998). Thus, the rat model is 
consistent with effects that are produced in humans who consume MDMA and 
increase their intake over time. Consequently, it is important to consider the 
effects of a down-regulated SERT in a rat model. 
Pharmacogenetic studies in humans have shown that carriers of the 
short (s-) allele of the SERT linked polymorphic region (5-HTTLPR) of the solute 
carrier 6 member 4 (SLC6A4) gene (leading to a 50% reduction in SERT activity 
(Lesch et al., 1996)) are more likely to abuse psychostimulants, such as cocaine 
and methamphetamine (Cao et al., 2013; Gerra et al., 2007). While abuse of 
MDMA has not been considered, use of MDMA is not significantly higher in these 
individuals (Martín-Santos et al., 2010; Roiser et al., 2005), although there was a 
trend for increased use in s/s genotypes in Martín-Santos et al. (2010). Given 
that these studies used the biallelic distinction of the 5-HTTLPR (i.e. only 
considered the s- and the l-allele, not the various versions of the l-allele), which 
fails to account for additional polymorphisms in the alternate long (l-) allele 
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that also lead to a reduction in SERT activity, these findings are likely to be 
underestimated. Importantly, s-allele carriers have been found to be more 
sensitive to some of the effects of MDMA on the central nervous system, 
including attention deficits, impaired emotional processing, risky choice 
making, increased mood disorders, and sedation (Cuyàs et al., 2011; Martín-
Santos et al., 2010; Pardo-Lozano et al., 2012; Roiser et al., 2005; Roiser et al., 
2006). While cognisant of the need for judicious translation from animal data to 
humans, the data suggest that individuals with a lower SERT activity may be 
more sensitive to the reinforcing effects of MDMA.   
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Chapter 4: Normalising early life serotonin levels rescues mild anxiety-
like behaviour in SERT knock-out rats 
Genetic reductions in the serotonin reuptake transporter (SERT) protein 
have frequently been associated with pathological phenotypes in adulthood. For 
instance, humans with the short (s-) allele of the SERT linked polymorphic 
region (5-HTTLPR) are more likely to be anxious, depressed, and abuse illicit 
drugs such as cocaine, methamphetamine, and heroin (Cao et al., 2013; Caspi et 
al., 2003; Enoch et al., 2011; Gerra et al., 2007; Heils et al., 1996; Lesch et al., 
1996; Sen et al., 2004).  Further, rodent models with genetically reduced SERT 
function (SERT-/-) also show anxiety- and depression-like behaviour (Holmes et 
al., 2003; Olivier et al., 2008), and SERT-/- rats, but not mice (Bengel et al., 1998; 
Sora et al., 2001) show increased sensitivity to both cocaine (Homberg et al., 
2008), and MDMA (Chapter 3), as well as altered behavioural response to 
MDMA (Chapter 2). However, the mechanisms underlying these altered 
characteristics are currently unknown.  
Due to the reduced ability of the SERT protein to transport extracellular 
serotonin (5-HT) back up into the presynaptic neuron, lymphoblast cell lines 
transfected with the s-allele showed a 50% reduction in [3H]5-HT uptake 
compared to l/l cells (Lesch et al., 1996). Similarly, SERT-/- rats exhibit a 9-fold 
increase in extracellular 5-HT (Homberg et al., 2007). Paradoxically however, 5-
HT reuptake inhibitors, or SSRIs, which result in increased extracellular 5-HT 
through blockade of the SERT, are commonly prescribed for their ability to 
decrease anxiety and depression, and have even been shown to reduce the 
rewarding efficacy of cocaine in rats (Carroll et al., 1990a). Given that SSRIs are 
commonly prescribed in adulthood, while potential genetic reductions in the 
SERT will be present from very early on in development, it is possible that the 
negative effects of genetic reductions in the SERT are mainly due to excessive 
extracellular 5-HT during early development.  
Indeed, 5-HT is known to play a wide role in neurodevelopment, acting 
as a developmental signal in neuronal processes such as neuronal migration, 
cell division and cell differentiation (For review see (Gaspar et al., 2003)). There 
is evidence that disruptions in 5-HT homeostasis during neural development 
can lead to psychiatric disorders. For instance, gestational use of SSRIs has been 
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associated with a 3-fold increase in autism in boys (Harrington et al., 2014), as 
well as increased internalising behaviours in 3 year olds (Oberlander et al., 
2010). However, no studies have yet tracked offspring beyond childhood, so it 
remains unknown whether further difficulties develop, or existing 
abnormalities persist into adulthood. Moreover, it is difficult to tease apart the 
effects of maternal depression and antidepressant treatment on offspring.  
Nonetheless, studies in animals, which can more easily overcome the 
aforementioned issues associated with human research, support the hypothesis 
that exposure to SSRIs during neonatal development leads to pathological 
phenotypes in adulthood. For example, postnatal SSRI exposure leads to 
increased anxiety- and depression-like behaviours, as well as increased 
sensitivity to the reinforcing properties of cocaine (Ansorge et al., 2008; 
Ansorge et al., 2004; Forcelli & Heinrichs, 2008; Olivier et al., 2011). 
Interestingly, decreasing postnatal 5-HT also leads to pathological outcomes: 
neonatal depletion of the 5-HT precursor L-tryptophan (TRP), resulting in 
decreased extracellular 5-HT, also leads to anxiety- and depression-like 
behaviours in rodents (Zhang et al., 2006; Zoratto, Fiore, Ali, Laviola, & Macrì, 
2013), while mice with a conditional knock-out of the 5-HT1a receptor (5-HT1a-
/-), in which the activation of 5-HT1a receptors by 5-HT is prevented, display 
increased anxiety-like behaviour only when synthesis of the 5-HT1a receptor is 
turned off during postnatal development, but not during adulthood (Gross et al., 
2002).  
Given the important role 5-HT plays in the development of anxiety and 
depression, it is important to establish whether early intervention can prevent 
the pathological phenotype associated with the genetic reduction of SERT. In a 
previous study, neonatal exposure to the 5-HT neurotoxin para-
chlorophenylalanine (pCPA) has been shown to rescue disrupted rapid eye 
movement (REM) sleep in SERT-/- mice (Alexandre et al., 2006). This effect 
appears to be driven by the inability of 5-HT to excessively activate the 5-HT1a 
receptor in pCPA treated SERT-/- mice: When neonatal 5-HT1a receptor 
activation was blocked by the 5-HT1a antagonist WAY100635 in SERT-/- mice 
their depression-like behaviour was rescued. However, while SERT-/- mice 
normally exhibit down-regulated 5-HT1a receptor binding, these levels were 
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mostly unchanged in the rescued SERT-/- mice. The aforementioned study in 
conditional 5-HT1a-/- mice also support the role of 5-HT1a receptor activation 
during early development in mediating normal anxiety-like behaviour (Gross et 
al., 2002). However, given the low number of studies, and that they have only 
been performed in mice, the mechanism by which the behaviour is rescued is 
still far from clear.  
Importantly, no one has yet attempted to rescue the behaviour of SERT-/- 
rats. This is particularly crucial given species differences between mice and rats 
in the physiological response to 5-HT1a antagonists and to genetic alterations in 
the SERT. For instance, while the 5-HT1a antagonist 8-OH-DPAT induces 
hypothermia in both mice and rats, this is mediated by the presynaptic 5-HT1a 
autoreceptor in the mice, but the postsynaptic 5-HT1a receptor in rats (Bill et 
al., 1991). Likewise, as was discussed in Chapter 3, while SERT-/- rats show 
significantly increased MDMA self-administration, SERT-/- mice show abolished 
MDMA self-administration (Trigo et al., 2007). Therefore, the aim of the current 
study was to reduce the 5-HT levels of SERT-/- rats during early development, 
and determine whether this intervention rescues their anxiety-like phenotype 
as assessed by the novelty supressed feeding (NSF) and open field tasks. While 
Alexandre and colleagues (2006) injected pCPA into pups, drug exposure in 
young rats is extremely distressing, with injections during early life leading to 
increased anxiety-like behaviour in adulthood (Girardi, Zanta, & Suchecki, 
2014). Moreover, given that SERT-/- rats exhibit increased sensitivity to 
anxiogenic situations (Olivier et al., 2008), the use of an alternative, less 
invasive, technique was desirable. Accordingly, dams were fed a TRP depleted 
diet immediately following birth. While this technique has been performed 
previously e.g. (Zhang et al., 2006; Zoratto et al., 2013), its use has been 
infrequent, and never been performed before in our lab. Therefore we first 
performed a pilot study to assess the optimal concentration of TRP before 
implementing the actual study with SERT-/- rats.  
Additionally, in order to investigate a mechanism for any apparent 
behavioural changes, gene expression of both 5-HT1a receptor and long 3’ 
untranslated region brain-derived neurotropic factor (long 3’UTR BDNF) were 
assessed. The 5-HT1a receptor was selected given its aforementioned 
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involvement in the anxiety- and depression-like behaviour of mice (Alexandre 
et al., 2006; Gross et al., 2002). Moreover, the 5-HT1a receptor is down-
regulated in the SERT-/- rats (Homberg et al., 2008), giving some support for the 
hypothesis. Likewise, BDNF is decreased in the leukocytes of both s-allele and 
other low functioning SERT polymorphisms (Molteni et al., 2010). Furthermore, 
total BDNF, as well as the long 3’UTR BDNF and other BDNF transcripts, are 
down-regulated in SERT-/- rats in the hippocampus and the pre-frontal cortex 
(PFC) (Calabrese et al., 2015; Molteni et al., 2010). This decreased expression of 
both total BDNF and the long 3’UTR BDNF develops from around postnatal day 
(P) 0 - P7 (Calabrese et al., 2013), indicating that this disruption occurs very 
early on in brain development. 
Accordingly, it is hypothesised that the anxiety-like phenotype normally 
observed in SERT-/- rats, as well as the normally down-regulated mRNA of both 
long 3’UTR BDNF and 5-HT1a, will be rescued following neonatal TRP depletion. 
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Experiment 1: Early life tryptophan depletion 
 
As neonatal TRP depletion has not been widely used previously, a pilot 
study was run with standard Sprague Dawley rats to determine optimal TRP 
levels for the experimental group. Control groups were fed 0.2g TRP / 100g diet 
(based on (Benevenga, Gahl, Crenshaw, & Finke, 1994)) while experimental 
groups were fed either 0.1g TRP / 100g  diet or 0.0g TRP / 100g diet. Anxiety-
like behaviour was then assessed in adulthood, followed by sensitivity to the 
locomotor activating effects of amphetamine in order to determine dopamine 
(DA) sensitivity.  
Method 
Subjects and General Protocols 
Sprague Dawley dams were fed an experimental diet containing varying 
amounts of TRP from P0 until P20. Five female offspring per group were 
sacrificed directly following diet completion, while the remaining offspring 
were weaned at P30 (0.0g TRP n = 26; 0.1g TRP n = 17; Control n = 19). Male 
pups were weighed at P21, P30 and P60 to determine any weight changes 
resulting from the experimental diet. Behavioural testing was performed from 
P60 onwards, with anxiety-like behaviours first assessed using the NSF task, 
followed 1 week later by amphetamine-induced locomotor activity in the open 
field. Open field data were extracted from the first 5 minutes of the habituation 
phase occurring at the beginning of amphetamine-induced locomotor activity 
testing.   
All animals were bred and reared at the vivarium of the School of 
Psychology at Victoria University of Wellington and housed in groups of three to 
four in hanging polycarbonate cages in a temperature (19 - 21 oC) and humidity 
(55%) controlled room. Animals were kept on a normal 12 hr light/dark cycle 
(lights on from 07.00 – 19.00 h), with testing being conducted during the light 
phase. Aside from testing hours, water and food were available ad libitum. All 
protocols were approved by the Victoria University of Wellington Animal Ethics 
Committee (AEC-2013R6). 
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Diet  
All groups were fed ad libitum with a cornflour based diet (Table 4.1) 
modelled on that used previously (González et al., 2008). Cornflour (Maseca, 
Azteca Milling Ltd, Texas) was selected due to its extremely low TRP content 
(0.045g / 100g)(González et al., 2008) to which TRP could be supplemented.  
 
Table 4.1. 
Experimental Diet Composition 
 Portion (g) 
 TRP 0.2g/100g TRP 0.1g/100g TRP 0.0g/100g 
Corn flour 91.2 91.3 91.4 
Soya oil 4.5 4.5 4.5 
Vitamin and mineral mix 4.1 4.1 4.1 
L- tryptophan 0.2 0.1 0.0 
Total 100 100 100 
 
Diets contained varying amounts of TRP: Experimental groups were fed a 
diet containing either 0.0g TRP or 0.1g TRP per 100g diet, while control groups 
were fed a diet of 0.2g TRP per 100g diet in order to gain the required amount 
of TRP for normal development (Benevenga et al., 1994). A vitamin and mineral 
mix (Berocca® Performance, Bayer) was added to prevent malnutrition from B 
vitamin deficiency. The amount of vitamin tablets per 100g diet was determined 
by comparing the contents of the tablets to a standard commercial mix (Teklad 
mix, Category numbers 40060 and 170760, Harlan Laboratories) as displayed in 
Table 4.2. On the basis of these comparisons it was decided 3 pills would be 
incorporated per 100g mix. Soya oil was also added to the diet to help binding. 
Soya oil amounts were based on those used previously (González et al., 2008). 
Vitamin and mineral mix pills were soaked in 25 ml of distilled H2O overnight, 
added to dry ingredients along with ~150 ml of distilled H2O, and then mixed to 
form a dough. Pellets were formed from the dough and dehydrated at 30 oC 
overnight.  
The experimental diet was available ad libitum from P0 until P20 (based 
on (González et al., 2008). As this was the first time this protocol was used in 
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our lab, all dams were given the control diet for 24 hours, 2 weeks post mating, 
to habituate dams to the food. 
 
Table 4.2.  
Comparison of standard Vitamin/Mineral Mix to Berocca® Perfomance tablets 
 Substance 
 Berocca® (mg /tablet) Teklad Mix (mg/kg) 
Magnesium 100 100 
Calcium 100 293 
Zinc 10 n/a 
Vitamin B12 0.01 3 
Vitamin H 0.015 0.44 
Folic acid 0.04 0.2 
Vitamin B1 and B2 15 2.2 
 
HPLC  
Following diet completion, 5 females from each group were sacrificed for 
monoamine analysis using high performance liquid chromatography (HPLC) in 
order to ensure the manipulation was successful. On P20 rats were taken 
between 09:00 and 14:00 hours and sacrificed by CO2 asphyxiation. Rats were 
decapitated and brains rapidly removed and dissected on ice. Brains were 
placed dorsally in a metal brain matrix and razor blades were places in parallel 
slice channels producing 1 or 2 mm slices based on the protocol outlined by 
Heffner, Hartman, and Seiden (1980). Sections were placed on a glass petri dish 
on ice, and hippocampus and caudate putamen were dissected and placed in 1.5 
mL Eppendorf tubes that had been previously weighed. Brain regions were 
weighed and stored immediately at -80 oC. Concentrations (ng / mg) of 5-HT, 
DA, norephinephrine (NE), and the 5-HT metabolite 5-Hydroxyindoleacetic acid 
(5-HIAA), as well as the DA metabolites 3,4-Dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) in both the hippocampus and the caudate 
putamen were determined via HPLC (100 series, Agilent). Samples were 
homogenised in 10 µL 0.1 N perchloric acid per mg of tissue and centrifuged at 
13,000 rpm at 4 oC for 30 minutes. The supernatant was filtered into vials and 
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injected into the column in pseudorandom order (C18 reversed phase; Agilent 
Eclipse XDB-C18, 4.6  150 mm, 5 m particle size) and the mobile phase 
consisted of 75 mmol/L NaH2PO4, 1.7 mmol / L octanesulfonic acid, 0.25 mmol / 
L EDTA, 100 L / l triethylamine, 10% (v/v) acetonitrile, pH 3, delivered at a 
constant flow rate of 1.0 ml / min. The injection volume and sensitivity were 
altered based on brain region (hippocampus: injection volume: 20 μl, sensitivity 
500nA; caudate putamen: injection volume: 20 μl, sensitivity: 2nA). 
Chromatograms were acquired with Agilent software and peak heights of 
samples were compared to peak heights of standards with known 
concentrations of 5-HT, DA, NE, 5-HIAA, DOPAC, and HVA. Regression analysis 
of the calibration curves was then used to calculate the concentration of the 
neurochemicals. Turnover rates for 5-HT and DA were calculated by dividing 
the metabolite concentration by the monoamine concentration. 
 
Amphetamine Locomotor Activity and Open Field 
Locomotor activity was assessed in open field activity systems consisting 
of eight clear Plexiglas activity chambers (42 x 42 x 30 cm) set in sound-
attenuated chambers (ENV-515-16, Med Associates Inc., Vermont). Location 
was tracked using 2 pairs of 8 evenly spaced infrared sources and sensors 
positioned perpendicular to one another around the chambers, and recorded by 
a commercially available software package (Med-PC IV, Med Associates Inc., 
Vermont). The infrared beams divided the chamber into squares, with a region 
set to the approximate dimensions of a rat (3 x 3 squares) generated around the 
rat. Any beam breaks within this region were counted as stereotypy. These 
movements have previously been shown to predominantly comprise of forepaw 
treading and head weaving (Baumann et al., 2008). One ambulatory count was 
registered if 3 beams were successively broken within 1000ms outside the 
region. One rearing count was registered if a second set of infrared beams 
placed 15 cm above the ground was broken. A white noise generator masked 
extraneous auditory disturbance during testing, and the room was illuminated 
with red light. Prior to and following each behavioural test session, the chamber 
interiors were cleaned and wiped with Virkon ‘S’ disinfectant (Southern 
Veterinary Supplies, Palmerston North, New Zealand).  
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On the day of testing, animals were first habituated to the activity 
chambers for 30 min. Open field data were collected from the first five minutes 
the animals were in the chamber. Animals were injected following the 30-
minute habituation phase with 0.5 mg/kg i.p. amphetamine and remained in the 
chamber for another 60 minutes. This dose was chosen as it was both relatively 
low, while still being behaviourally active within this paradigm (Joyce & Koob, 
1981). 
 
Novelty Supressed Feeding 
Novelty supressed feeding testing was performed in a dimly lit room 
using a large circular arena (1 m diameter), the base of which was covered with 
a layer of bedding and contained a circular piece of paper, upon which was 
placed a single food pellet (approx. 2 g). Subjects were food deprived for 24 
hours prior to the start of the experiment. Upon test commencement, the 
subject was placed in a designated section on the side of the chamber, and the 
timer was started. The experiment was terminated when the rat obtained the 
food pellet or following 10 minutes, whichever occurred first. The latency to 
initiate feeding was recorded, and the rat was immediately removed and fed. 
The chamber was cleaned between subjects using 70% ethanol, and fresh 
bedding, paper, and food applied to the chamber floor. Data were recorded 
using EthoVision software (Version 9.1).  
 
Drugs 
d-amphetamine was obtained from Environmental Science and Research 
(Porirua, New Zealand). Amphetamine was dissolved in a sterile solution of 
0.9% physiological saline and administered at a volume of 1 ml / kg body 
weight. All weights refer to the anhydrous salt and not the acid. 
 
Data analysis 
Offspring weight percentage change, HPLC, open field and NSF data were 
analysed using a one way analysis of variance (ANOVA) with TRP group as a 
between subjects factor. Follow up Tukey Honestly Significant Difference post-
hoc tests were employed where necessary. For amphetamine-induced 
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locomotor activity, a two-way ANOVA was run with TRP group and drug group 
as between subjects factors. Although no interactions were present, exploratory 
independent t-tests were used in order to elucidate potential patterns, with 
equal variances not assumed if Levene’s test for equality of variances was 
significant. Due to technical difficulties, the data for 5 rats were lost for open 
field analysis. Extreme outliers were identified using SPSS’s outlier test and 
removed. All tests were run using IBM SPSS Statistics version 22 for windows. 
Alpha level was set at p < .05 for all data. 
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Results 
 
Offspring weights  
There was no difference between treatment groups for percentage 
weight change between P20 to P 30, F2,61 = .92, p = .4,  or from P 30 to P60, F2,61 
= .07, p = .94, Figure 4.1.  
 
Figure 4.1. Offspring weights as a function of age (P20, P30 and P60) for all for litters neonatally 
TRP-deprived (0.0g or 0.1g TRP per 100g diet, n = 26 and 17 respectively) as well as controls 
(0.2g TRP per 100g diet, n = 19). Lines represent the mean (+SEM). * p < .05 
 
HPLC 
There was a tendency for decreased 5-HT levels after early life low TRP 
exposure in both the hippocampus, F2,12 = 3.23, p = .08 (Figure 4.2a), as well as 
the caudate putamen, F2,12 = 3.27, p = .07 (Figure 4.3a) at P20. Moreover, there 
was a significant dose dependent decrease in 5-HIAA in both the hippocampus, 
F2,12 = 7.74, p = .01 (Figure 4.2b), as well as the caudate putamen, F2,12 = 8.78, p < 
.001 (Figure 4.3b). Follow up post-hoc tests indicated this difference was 
between the 0.0g TRP and 0.2g TRP groups in the hippocampus (p = .01), and 
between the 0.0g TRP groups and both the other groups in the caudate putamen 
(0.1g TRP: p = .01; 0.2g TRP: p = .01).  
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Figure 4.2. Hippocampus concentrations (ng/mg) of 5-HT, 5-HIAA, NE, DA, HVA, and DOPAC (A-
F), plus 5-HT and DA turnover (G-I) for females neonatally TRP-deprived (0.0g or 0.1g TRP per 
100g diet) as well as controls (0.2g TRP per 100g diet). n = 5 per group. Bars represent the mean 
(+SEM). * p < .05 
 
There was also a significant effect on 5-HT turnover in the hippocampus, 
F2,12 = 7.06, p = .01 (Figure 4.2g), though this was not significant in the caudate 
putamen, F2,12 = 1.61, p = .24 (Figure 4.3g). Follow up tests indicated this 
difference in the hippocampus was between the 0.0g TRP group and both other 
groups (0.1g TRP: p = .01; 0.2g TRP group: p = .04).  
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Figure 4.3.  Caudate putamen concentrations (ng / mg) of 5-HT, 5-HIAA, NE, DA, HVA, and DOPAC 
(A-F), plus 5-HT and DA turnover (G-I) for females neonatally TRP-deprived (0.0g or 0.1g TRP per 
100g diet) as well as controls (0.2g TRP per 100g diet). n = 5 per group. Bars represent the mean 
(+SEM). * p < .05. 
 
Moreover, while there were no differences between groups for DA or its 
metabolites in either the hippocampus (DA: F2,12 = 2.6, p = .12, Figure 4.2d; HVA: 
F2,12 = 1.2, p = .34, Figure 4.2e; DOPAC: F2,12 = 2.67, p = .11, Figure 4.2f), or the 
caudate putamen (DA: F2,12 = .66, p = .54, Figure 4.3d; HVA: F2,12 = .27, p = .77, 
Figure 4.3e; DOPAC: F2,12 = 2.28, p = .15, Figure 4.3f), there was a significant 
treatment effect on DA turnover in the hippocampus, with decreased TRP dose-
dependently decreasing DA turnover (HVA/DA: F2,12 = 3.97, p = .05, Figure 4.2h; 
DOPAC/DA: F2,12 = 6.39, p = .01, Figure 4.2i). Follow up tests indicated that 0.0g 
TRP differed significantly from 0.2g TRP (HVA/DA: p = .04; DOPAC/DA: p = .01). 
There was no effect on DA turnover in the caudate putamen (HVA/DA: F2,12 = .26, 
p = .77, Figure 4.3h; DOPAC/DA: F2,12 = 1.49, p = .26, Figure 4.2i). Finally, there 
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was no significant treatment effect on NE in either the hippocampus, F2,12 = 3.30, 
p = .07 (Figure 4.2c), or caudate putamen, F2,12 = .99, p = .40 (Figure 4.3c). 
 
Anxiety Related Tests   
Open Field. There was no significant effect of TRP group on time spent 
in the centre of the open field, F2,53 = .58, p = .56, or on distance travelled F2,53 = 
1.5, p = .23, indicating that neonatal TRP depletion did not affect activity 
measured in the open field task (Figure 4.4). 
 
Figure 44.  A) Time spent in the centre of the open field (s), and B) distance travelled in the open 
field (cm), during a 5 minutes novel exposure in rats neonatally TRP-deprived (0.0g or 0.1g TRP 
per 100g diet, n = 23 and 16 respectively) as well as controls (0.2g TRP per 100g diet, n = 17). 
Bars represent the mean (+SEM). * p < .05 
 
Novelty Supressed Feeding. As indicated in Figure 4.5, a significant 
difference between groups was observed, F2,56 = 4.21 , p = .02, with post-hoc 
tests indicating there was a significant difference between the 0.0g and 0.2 TRP 
groups (p = .02). This indicates that neonatal TRP depletion dose dependently 
increased latency to feed. 
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Figure 4.5.  Latency to begin eating a food pellet in an open arena following 24 hours of food 
deprivation in animals neonatally TRP-deprived (0.0g or 0.1g TRP per 100g diet, n = 26 and 16 
respectively) as well as controls (0.2g TRP per 100g diet, n = 19). Bars represent the mean (+SEM). 
* p < .05 
 
Amphetamine locomotor activity  
There was no effect of group for baseline ambulatory counts F5,42 = .36, p 
= .87, rearing F5,42 = .24, p = .94, or stereotypy, F5,42 = .78, p = .57. Amphetamine 
increased forward locomotion across all groups F1,50 = 12.57, p < .001, however 
there was no effect of TRP group F2,50 = .82, p = .45, and no interaction, F2,50 = 
.79, p = .46 (Figure 4.6a). Given the apparent trend of increased forward 
locomotion in the 0.0g TRP group compared to the other two groups, 
exploratory post-hoc t-tests were run. These indicated that, while there was a 
significant effect of amphetamine in the 0.0g TRP group t12.57= -2.9, p = .01, there 
was no significant effect of amphetamine in the other TRP groups (0.1g TRP: t14 
= -1.59, p = .13; 0.2 TRP: t15 = -1.70, p =.11).  
While amphetamine increased rearing across all groups F1,50 = 7.01, p = 
.01, there was no effect of TRP group F2,50 = .85, p = .43, and there was no 
interaction, F2,50 = .701, p = .50 (Figure 4.6b). Again, given the apparent trend of 
decreased rearing in the 0.0g and 0.1g TRP groups following amphetamine 
compared to control, exploratory post-hoc t-tests were run. These indicated 
that there was a significant effect of amphetamine on rearing in the 0.2g TRP 
group t9.93 = -2.65, p = .03, but no significant effect of amphetamine on rearing 
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for the 0.1g TRP condition t8.09 = -1.15, p = .28, or the 0.0g TRP group t15 = -.90, p 
= .38. 
 
Figure 4.6. Psychomotor effects of either 0.5 mg / kg amphetamine or saline in neonatally TRP-
deprived (0.0g or 0.1g TRP per 100g diet) as well as controls (0.2g TRP per 100g diet) animals. 
Graphs display A) ambulation, B) rearing, and C) stereotypy. 0.0g TRP: saline n = 11, amphetamine 
n = 12; 0.1g TRP: saline n = 8, amphetamine n = 8; 0.2g TRP: saline n = 9, amphetamine n = 8. Bars 
represent the mean (+SEM). * p < .05 between drug treatments, # p <  .05 in exploratory post-hoc 
t-tests. 
  
Last, while amphetamine treatment increased stereotypy across all 
groups F1,50 = 19.13, p < .01, there was no effect of TRP group F2,50 = .65, p = .52, 
and no interaction, F2,50 = .29, p = .75 (Figure 4.6c). These findings indicate that 
amphetamine increased forward locomotion, rearing, and stereotypy, while 
there is some suggestion that acute amphetamine resulted in increased 
ambulation, but decreased rearing, in animals that had been neonatally TRP-
deprived. 
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Comment 
HPLC results confirmed neonatal TRP depletion led to a significant 
decrease in 5-HIAA in the hippocampus and the caudate putamen, as well as a 
trend for 5-HT decrease. Moreover, neonatal TRP depletion resulted in an 
increase in 5-HT turnover in the hippocampus, indicating the manipulation was 
successful, with the effect being much stronger in the group that received the 
0.0g TRP per 100g diet. Moreover, while NE and DA metabolites were 
unaffected, there was a trend for increased DA levels in the hippocampus, which 
lead to a significant decrease in DA turnover in the hippocampus, indicating that 
reducing 5-HT influences DA expression. In adulthood, neonatally TRP-deprived 
rats showed an increase in anxiety-like behaviour as measured by the NSF task, 
but not the open field. Moreover, there was some support for an increase in 
sensitivity to the psychomotor effects of amphetamine in these animals. Taken 
together, the results from this pilot study indicate this manipulation is strong 
enough to affect anxiety-like, and possibly dopaminergically mediated, 
behaviours. Based on these findings, the 0.0g TRP / 100g diet was selected as 
the experimental dose given that it was both much more successful in 
decreasing 5-HT tone, as well as inducing behavioural changes, though not so 
strong as to induce severe physical deficits. However, it should be noted that, 
while Sprague-Dawley rats were used in the pilot (experiment 1), Wistar rats 
are used in the experiment proper. While this was necessary due to resource 
constraints, there exist considerable differences between strains. Consequently, 
few conclusions will be drawn from this pilot study.  
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Experiment 2: Early life tryptophan depletion in SERT knock-out rats 
Method 
 
Subjects and General Protocols 
Serotonin transporter knockout rats (SLC6A41Hubr, SERT-/-) were 
originally created via N-ethyl-N-nitrosourea (ENU)-induced mutagenesis in a 
commercial (Harlan, Ter Horst, The Netherlands) wild-type Wistar rat (Smits et 
al., 2006). Experimental animals were generated by breeding pairs of SERT-/-, or 
SERT+/+ fathers with SERT+/- mothers. Originally homozygous breeding has 
been attempted for SERT-/- animals, however poor maternal care exhibited by 
SERT-/- mothers resulted in low offspring survival. Offspring resulting from non-
homozygous breeding were genotyped at the end of the experiment. Following 
brain extraction, tail cuts were taken for genotyping (performed at Transnetyx, 
Cordova, USA). Dams were given an experimental diet containing either a 
control amount of TRP (0.2g per 100g diet), or no TRP (0.0g per 100g diet), 
from P0 until P20. Five female and five male SERT-/- offspring per group were 
sacrificed directly following diet completion, while remaining animals were 
weaned at P30. Anxiety-like behaviour was assessed from P60 for remaining 
SERT+/+ and SERT-/- animals (Male SERT+/+ 0.0g TRP n = 26, 0.2g TRP n = 15, 
SERT-/- 0.0g TRP n = 9, 0.2g TRP n = 5; Female SERT+/+ 0.0g TRP n = 11, 0.2g TRP 
n = 14, SERT-/- 0.0g TRP n = 9, 0.2g TRP n = 11), first using the open field, 
followed 1 week later by NSF. Two weeks following NSF, rats were sacrificed by 
CO2 asphyxiation followed by decapitation. Brains were immediately frozen in 
an -80 oC freezer. Brains were later dissected and RNA was isolated for qPCR (N 
= 7-9 per group, aside from SERT-/- 0.2g TRP per 100g diet males, for which n = 
4). 
All animals were bred and reared at the vivarium of the School of 
Psychology at Victoria University of Wellington and housed in groups of three to 
four in hanging polycarbonate cages in a temperature (19 - 21 oC) and humidity 
(55%) controlled room. Animals were kept on a normal 12 hr light / dark cycle 
(lights on from 07.00 – 19.00 h), with testing being conducted during the light 
phase. Aside from testing hours, water and food were available ad libitum. All 
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protocols were approved by the Victoria University of Wellington Animal Ethics 
Committee (AEC-2013R6). 
 
Diet 
Based on the results from the pilot study, the 0.0g TRP / 100g diet was 
chosen for the experimental diet. Diet composition and schedules are identical 
to those described in Experiment 1. 
 
HPLC 
As with Experiment 1, following diet completion, 5 animals from each 
group (TRP and sex) were sacrificed for monoamine analysis using HPLC in 
order to ensure the manipulation was successful. Both male and female SERT+/+ 
rats were used in order to discern whether any sex differences existed. Only 
SERT+/+ rats were used due to the low number of SERT-/- rats available, with 
those SERT-/- born reserved for behavioural testing. Briefly, on P20 rats were 
taken between 09:00 and 14:00 hours and sacrificed by CO2 asphyxiation. 
Structures were dissected as previously described and stored at -80 oC. 
Monoamine plus metabolite concentrations (5-HT, 5-HIAA, DA, DOPAC, HVA, 
NE) for the prefrontal cortex (PFC) were determined via HPLC (injection 
volume: 20μl, sensitivity: 500nA). All other methods are identical to those 
described in Experiment 1. 
 
Anxiety Related Tests  
In the open field task animals were removed from the activity chamber 
immediately once 5 minutes had elapsed. Apparatus and further procedures 
used, as well as all novelty supressed feeding methods, are identical to those 
described in Experiment 1. 
 
RNA preparation and gene expression analysis by real time quantitative 
polymerase chain reaction (qPCR) 
RNA extraction and purification. Brains were partially defrosted to -10 
oC +/- 2 oC and the PFC was dissected using the method described previously 
(Experiment 1, current chapter). This region was selected based on previous 
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findings that the PFC is particularly sensitive to alterations in long 3’UTR BDNF 
in SERT-/- rats (Calabrese et al., 2015; Molteni et al., 2010). Tissue was placed in 
1.5 mL Eppendorf tubes and immediately placed on dry ice, then stored at -80 
oC. RNA was isolated from the PFC only. RNA was isolated using a guanidine 
isothiocyanate-phenol-chloroform extraction using TRIzol® reagent (Life 
Technologies) in accordance with the manufacturer’s instructions. Tissue was 
homogenised in TRIzol® reagent (500 μL to max 50 g tissue) and incubated at 
room temperature for 5 minutes. To this, 100 μL of chloroform was added and 
tubes were inverted 10 times and incubated at room temperature for 2-3 
minutes. Samples were centrifuged at 12,000 g for 15 minutes at 4 oC. The upper 
aqueous phase was removed and added to a new RNase free 1.5 mL Eppendorf 
tube. To this, 250 μL isopropanol was added and tubes were mixed by inverting, 
followed by incubation at room temperature for 10 minutes. Tubes were 
centrifuged at 12,000 g for 10 minutes at 4 oC. The supernatant was removed 
and 500 μL of 75% ethanol was added to the pellet. Tubes were vortexed briefly 
and then centrifuged at 7500 g for 5 minutes at 4 oC. The supernatant was 
removed and the pellet was air-dried either until the ethanol had evaporated or 
a maximum of 10 minutes. To this, 52 μL of RNase-free H2O was added to 
rehydrate the pellet and tubes were incubated at 55 oC in a water bath for 15 
minutes.  
Quantification and integrity of RNA. The samples were quantified 
using a Nanodrop spectrophotometer (Nanodrop 2000, Thermo Scientific). A 2 
μL aliquot of RNase-free H2O was loaded onto the Nanodrop as a blank, 
followed by a 2 μL aliquot of sample. The Nanodrop provided measurements of 
RNA concentration (ng / ml), as well as measurements of purity (A260/280 and 
A260/230) for each RNA sample. Following this, RNA quality was determined 
using agarose gel electrophoresis. As different size particles migrate though the 
gel at different rates, agarose gel electrophoresis can determine whether the 
sample contains any DNA contamination, indicated by separated bands, or RNA 
degradation, indicated by visible smearing of bands. A 1% agarose gel was used 
consisting of 1g agarose, 100 mL distilled H2O and 5 μL of SYBR® safe DNA gel 
stain (Life Technologies) and was manually cast. Gel was placed in the 
electrophoresis container (Bio-Rad) and filled with 
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tris(hydroxymethyl)aminomethane-acetate-ethylenediaminetetraacetic acid 
(TAE) running buffer (20 mL 50% TAE to 1 L deionised H2O). A 1 μL aliquot of 
the RNA sample along with 9 μL RNase free H2O and 2 μL of 6x loading dye 
(Thermo Scientific) were loaded into the gel wells. Five μL 1Kb DNA ladder 
(Thermo Scientific) was placed in the first and last wells. The gel was run at 90V 
for 30 minutes. Gels were then examined on an ultra violet transilluminator 
(ChemiDoc, Bio-Rad) using Bio-Rad software (Image LabTM 5.0 Software).  
Reverse Transcription Polymerase Chain Reaction (RT-PCR). RNA 
was then converted into complementary deoxyribonucleic acid (cDNA) in 
preparation for the qPCR. Up to 2.5 μg of RNA was added to 4 μL of reverse 
transcriptase premix (SuperScript® VILOTM MasterMix, Life Technologies) and 
up to 20 μL of RNase/DNase free H2O. The mixture was gently mixed and 
incubated in a RT-PCR machine (Veriti Thermal Cycler ®, ThermoFischer 
Scientific) for the following cycles: 25 oC for 10 minutes; 42 oC for 60 minutes; 
85 oC for 5 minutes. Cycles were then terminated. The undiluted cDNA was then 
stored at -20 oC until the qPCR.  
Real Time Polymerase Chain Reaction (qPCR). Samples were 
processed for qPCR to assess long 3’UTR BDNF, and 5-HT1a (HTR1a) mRNAs. 
The housekeeping genes used were Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and Beta-actin (ACTB). All primers were TaqMan® 
primer/probe based and ordered at Life Technologies (see Table 3). The qPCR 
reaction mix consisted of 40 μL RNase/DNase free H2O, 50 μL TaqMan® gene 
expression master mix (Applied Biosystems®, Life Technologies), 5 μL primer 
(TaqMan® Gene Expression Assays (20x), Life Technologies), and 1 μL aliquot 
of cDNA sample (20 ng). Samples were analysed in 96 well plates (Bio-Rad) that 
were covered and briefly centrifuged. Samples were run in triplicate with ‘no 
sample’ controls. Thermal cycling (c1000TM thermal cycler, Bio-Rad), was 
initiated with the incubation of 50 oC for 2 minutes (RNA retro transcription) 
followed by incubation at 95 oC for 10 minutes (TaqMan® polymerase 
activation). Following this, 40 - 50 PCR cycles were performed, consisting of 15 
seconds at 95 oC, to enable melting, followed by 1 minute of 60 oC, to enable 
annealing and extension reactions. 
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Table 4.3. 
Forward and reverse primers and probes purchased from Life Technologies. 
Gene Assay ID 
GAPDH Rn01775763_g1 
ACTB (Beta-actin) Rn00667869_m1 
HTR1a Rn00561409_s1 
long 3’UTR BDNF Rn02531967_s1 
 
Data Analysis 
For HPLC data, a two-way ANOVA was used with TRP group and sex 
entered as between subjects factors. Given that previous experiments were all 
performed using males alone, as well as variance in anxiety-like behaviour 
observed in females during different oestrous cycles (Frye, Petralia, & Rhodes, 
2000), sex was analysed separately for all tests. A two-way ANOVA was used 
with genotype and TRP group entered as between subjects factors. Follow up 
test following significant interactions were performed using independent t-
tests.  
The cycle at which the gene reached a detection threshold, or the 
quantification cycle (Cq) as well as the efficiency of the PCR plate were averaged 
and used to calculate the mean normalised gene expression (MNE) per sample. 
The Cq values of the target (5-HT1a and Long 3’ UTR BDNF) and reference 
genes (GAPDH and BACT) as well as the efficiency of the PCR reactions per 
sample were used to determine the MNE for the target genes. Values were then 
log transformed. Following this, considering sex separately, a two-way ANOVA 
with genotype and TRP group entered as between subject factors was run to 
determine differences in log MNE between samples. 
Extreme outliers were detected using SPSS’s outlier test and removed. 
All tests were run using the IBM SPSS Statistics version 22 for windows. Alpha 
level was set at p < .05 for all data. 
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Results 
HPLC  
Monoamine concentrations following neonatal TRP depletion in SERT+/+ 
rats in the PFC are presented in Figure 4.7, with ANOVAs in Table 4.4. Overall, a 
TRP-free diet led to significant decrease in 5-HIAA and a significant increase in 
DOPAC in SERT+/+ rats in the PFC, and this did not differ between sexes.  
 
 
 
 
Figure 4.7.  PFC concentrations (ng/mg) of 5-HT, 5-HIAA, NE, DA, HVA, and DOPAC (A-F), plus 5-
HT and DA turnover (G-I) for SERT+/+ males and females neonatally TRP-deprived (0.0g TRP per 
100g diet) as well as controls (0.2g TRP per 100g diet). n = 5 per group. Bars represent the mean 
(+SEM). * p < .05. 
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Table 4.4.  
Two-way ANOVA results of TRP depletion on various monoamines and their 
metabolites in the PFC across sex within SERT+/+ rats. 
Monoamines Gender TRP Group Interaction 
5-HT F1,16 = .10, p = .76 F1,16 = 2.47, p = .14 F1,16 = .17, p = .69 
5-HIAA F1,16 = 1.43, p = 
.25 
F1,16 = 8.28, p = .01 * F1,16 = .23, p = .64 
5-HIAA/5-HT F1,16 = .14, p = .71 F1,16 = .11, p = .75 F1,16 = .72, p = .41 
DA F1,16 = .80, p = .38 F1,16 = .02, p = .88 F1,16 = .44, p = .52 
HVA F1,16 = .35, p = .56 F1,16 = .55, p = .47 F1,16 = .04, p = .85 
DOPAC F1,16 = 1.06, p = 
.31 
F1,16 = 10.53, p = .01 * F1,16 = .50, p = .48 
HVA/DA F1,16 = .04, p = .84 F1,16 = .09, p = .76 F1,16 = .09, p = .76 
DOPAC/DA F1,16 = .02, p = .90 F1,16 = .62, p = .44 F1,16 = .62, p = .44 
NE F1,16 = .06, p = .81 F1,16 = .82, p = .38 F1,16 = .82, p = .38 
*p < .05 
 
Anxiety Related Tests 
Open Field. For male subjects, a significant genotype by TRP group 
interaction for time spent in the centre of the open field was observed, F1,50 = 
6.18, p = .02 (Figure 4.8a). A main effect of genotype was also found, F1,50 = 
15.84, p < .001, although no main effect of TRP group was observed, F1,50 = 3.86, 
p = .06. Follow up t-tests indicated the interaction was driven by a significant 
difference between TRP-deprived SERT-/- and SERT+/+ subjects, t8.5 = 3.41, p = 
.01 in time spent in the centre compared to SERT+/+ rats, t43 = 1.64, p = .11. This 
indicates that male SERT-/- rats that were deprived of TRP spent significantly 
more time in the centre of the open field than TRP-deprived SERT+/+. For female 
subjects, no interaction between genotype and TRP group was observed, F1,41 = 
1.28, p = .27. However, female SERT-/- rats did spend more time in the centre of 
the open field compare with SERT+/+ rats, F1,41 = 15.01, p < .001 (Figure 4.8b), 
although no difference was observed between those deprived of TRP in early 
life and those not, F1,41 = .24, p = .62.  
 85 
 
 
Figure 4.8.  Time spent in the centre of the open field (s) for male (a) and female (b), and distance 
travelled in the open field (cm) for male (c) and female (d) SERT-/- and +/+ rats neonatally TRP-
deprived (0.0g TRP per 100g diet) as well as controls (0.2g TRP per 100g diet) during a 5 minutes 
novel exposure. Male SERT+/+ 0.0g TRP n = 26, 0.2g TRP n = 15, SERT-/- 0.0g TRP n = 9, 0.2g TRP n 
= 5; Female SERT+/+ 0.0g TRP n = 11, 0.2g TRP n = 14, SERT-/- 0.0g TRP n = 9, 0.2g TRP n = 11. Bars 
represent the mean (+SEM). * p < .05  
 
Neither males (Genotype: F1,41 = 2.88 p = .10; TRP group: F1,41 = 3.74, p = 
.06; Genotype x TRP group: F1,41 = 2.79, p = .10), nor females (Genotype: F1,50 = 
2.02, p = .16; TRP group: F1,50 = .012, p = .91; Genotype x TRP group: F1,50 = .35, p 
= .55) demonstrated any differences in distance travelled in the open field 
(Figure 4.8c-d). This indicates that the increased time spent in the centre of the 
open field demonstrated by TRP depleted SERT-/- rats is not driven by an 
increase in exploratory behaviour.  However, pooled analysis indicated a 
significant effect of sex, with females moving a greater distance compared with 
males (Figure 4.9), t123.53 = 5.15, p < .001 
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Figure 4.9.  Pooled data showing distance travelled in the open field (cm) during a 5 minutes 
novel exposure for male (n = 54) vs. female (n = 45) subjects. Bars represent the mean (+SEM). * 
p < .05. 
 
Novelty Supressed Feeding. As displayed in Figure 4.10a, male SERT-/- 
rats had a longer latency to feed than SERT+/+ F1,50 = 19.31 p < .001, regardless 
of TRP group, F1,50 = .65, p = .42. There were no interactions between genotype 
and TRP group observed, F1,50 = .01, p = .93. In females however (Figure 4.10b), 
while SERT-/- rats also had a longer latency to feed compared with SERT+/+ rats, 
F1,41 = 9.69, p < .001, neonatally TRP-deprived animals also showed increased 
latency to feed, F1,41 = 4.38, p = .04. No interaction between the two variables 
was observed, F1,41 =  .05 p = .83. 
 
Figure 4.10.  Latency to eat in food-deprived animals in the novelty supressed feeding task for 
male (a) and female (b) SERT-/- and +/+ rats neonatally TRP-deprived (0.0g TRP per 100g diet) as 
well as controls (0.2g TRP per 100g diet). Male SERT+/+ 0.0g TRP n = 26, 0.2g TRP n = 15, SERT-/- 
0.0g TRP n = 9, 0.2g TRP n = 5; Female SERT+/+ 0.0g TRP n = 11, 0.2g TRP n = 14, SERT-/- 0.0g TRP 
n = 9, 0.2g TRP n = 11. Bars represent the mean (+SEM). * p < .05 between genotypes, # p < .05 
between TRP groups. 
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qPCR  
Following RNA extraction, all samples were analysed for purity and 
quantity using a Nanodrop spectrophometer, as well as agarose gel 
electrophoresis to ensure quality. On the basis of these analyses, two samples 
were removed from further analyses as they did not contain enough RNA for 
qPCR testing. 
 
 
Figure 4.11. Log mean normalised gene expression (MNE) of BDNF (A,B) and 5-HT1a  (C,D) for 
male and female SERT-/- and +/+ rats neonatally TRP-deprived (0.0g TRP per 100g diet) as well as 
controls (0.2g TRP per 100g diet). N = 7-9 per group, aside from SERT-/- 0.2g TRP per 100g diet 
males, for which n = 4. Bars represent the mean (+SEM). 
 
As indicated in Figure 4.11a, expression of long ‘3 UTR BDNF in male 
subjects did not differ between genotypes, F1,25 = .07, p = .80, or TRP group F1,25 = 
.11, p = .74, and no interaction was present, F1,25 =  1.17, p = .29. Similarly, 
expression of 5-HT1a in males (Figure 4.11c) did not differ between genotypes, 
F1,25 = 1.4, p = .25, or TRP group F1,25 = .74, p = .40, and no interaction was found, 
F1,25 =  1.60, p = .22. Expression of BDNF in females (Figure 4.11b) also failed to 
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differ between both genotype, F1,27 = 1.40, p = .25, as well as TRP group F1,27 = 
1.93, p = .18, and no interaction was found, F1,27 =  .06, p = .81. Finally, expression 
of 5-HT1a in females demonstrated no difference between genotypes, F1,27 = .10, 
p = .76, TRP group F1,27 = .02, p = .89, and no interaction was found, F1,27 =  .09, p 
= .77 (Figure 4.11d).  
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Discussion 
The aim of the current study was to determine whether neonatal TRP 
depletion would rescue the anxiety-like behaviour normally found in SERT-/- 
rats. In line with our hypothesis, neonatal TRP depletion led to an increase in 
time spent in the centre of the open field in male SERT-/- rats. Intriguingly 
however, while there was no effect of neonatal TRP depletion, female SERT-/- 
rats spent more time in the centre of the open field, implying the female SERT-/- 
rats show less anxiety-like behaviour compared to their SERT+/+ counterparts. 
These alterations in time spent in the centre of the open field were not mediated 
by increased exploratory behaviour in the open field, however females did 
display an increase in distance travelled compared with male rats. These 
findings contrast with those observed in the NSF task, in which both male and 
female SERT-/- rats exhibited a longer latency to feed. However, while there was 
no effect of neonatal TRP depletion in male rats, it did lead to increased latency 
to feed in females. Finally, neither genotype, nor neonatal TRP depletion, 
affected the mRNA levels of either 3'UTR BDNF or 5-HT1a, in either sex. 
In contrast to a previous study assessing the anxiety-like behaviours of 
SERT-/- rats (Olivier et al., 2008), the current data do not reveal the anticipated 
genotype effect on time spent in the centre of the open field. Olivier et al. (2008) 
found that SERT-/- rats spent less time in the centre of the open field, and there 
was no difference between sexes. In contrast, while there was no genotype 
effect observed for male rats in the current data, female rats paradoxically 
displayed increased time spent in the centre of the open field, implying 
decreased anxiety-like behaviour compared with their SERT+/+ counterparts. 
Methodological differences likely underlie these incongruent findings. For 
instance, the open field used in the present study was much smaller than that 
used in Olivier et al. (2008), which measured 100 cm x 100 cm. Moreover, the 
open field in the current study was placed in a sound-attenuated chamber with 
a relatively low ceiling (approximately 15 cm above the walls), while Olivier et 
al. (2008) placed the open field in a normal room (i.e. the ceiling was more than 
a meter above the open field walls). It is therefore quite possible that the centre 
of the particular open field task used in the current study may not have 
produced such anxiety provoking conditions compared with that used by Olivier 
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et al. (2008). Nonetheless, the results show that mild anxiety was reversed by 
neonatal TRP depletion in SERT-/- males. 
Moreover, in contrast to the decreased anxiety-like behaviour displayed 
by females in the open field, both male and female SERT-/- showed increased 
anxiety-like behaviour in the NSF task. Any conclusions that female SERT-/- rats 
display less anxiety-like behaviour in the open field than their SERT+/+ 
counterparts are therefore limited. These findings are partially consistent with 
those previously described by Olivier et al. (2008) who found a genotype effect 
in male but not female SERT-/- rats in this task. Compared to their male 
counterparts, Olivier et al. (2008) found that female SERT+/+ rats exhibited an 
increased latency to feed (i.e. were more “anxious”), while female SERT-/- rats 
showed a decreased latency to feed (were less “anxious”). Consequently, the 
difference between genotypes apparent in males was absent in females. In the 
current study however, considering control TRP diet rats only, while female 
SERT-/- rats were also less “anxious” than their male counterparts, the latency to 
feed in SERT+/+ rats was consistent between sexes. Overall then, the differences 
between the two studies may be mediated by the performance of SERT+/+ 
females. This is possibly due to methodological differences. For instance, while 
Olivier et al. (2008) isolated animals for 24 hours prior to the NSF task, this was 
not possible in the current study given space constraints. Consequently, it may 
be that this isolation increased the sensitivity of SERT+/+ females to the 
anxiogenic conditions of the NSF task in Olivier et al. (2008) compared to the 
current study. 
Given that the open field task used in the current experiment was not as 
anxiety inducing as previous iterations, it is likely that the NSF was much more 
anxiogenic. It appears therefore, in male SERT-/- rats at least, neonatal TRP 
depletion was able to rescue mild anxiety, but not able to rescue more severe 
anxiety. This is most likely due to the TRP treatment itself, which was only able 
to produce a mild reduction in 5-HT functioning, as indicated by the HPLC 
findings. Indeed, previous ‘rescuing’ of the altered phenotype in SERT-/- mice by 
decreasing 5-HT during neonatal development used the 5-HT neurotoxin pCPA 
(Alexandre et al., 2006), a much stronger 5-HT reducing manipulation. 
However, in addition to the confound evident in administering distressing 
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injections during early life (Girardi et al., 2014), in pilot testing prior to the 
current study pCPA led to blindness across all genotypes, and its use was 
consequently terminated for ethical reasons. TRP depletion was consequently 
performed as a less severe alternative. Unfortunately, this manipulation may 
not have been strong enough to rescue anxiety in the more anxiogenic NSF task. 
Indeed, while TRP depletion did lead to a decrease in 5-HIAA, there was no 
significant decrease in 5-HT, although there was a trend. Moreover, instead of 
direct administration to pups, as occurs with pCPA, TRP depletion is 
transmitted to the pups indirectly via lactation. In line with previous studies, the 
depletion protocol was only enacted from P0 to P20, a protocol that has been 
successful in previous studies by González et al. (2008). However, many other 
studies have introduced TRP depletion from much earlier in development, some 
from prior to conception (Del Angel-Meza, Ramı́rez-Cortés, Olvera-Cortés, 
Pérez-Vega, & González-Burgos, 2001). However, given that previous studies 
have successfully induced mood disorder-like behaviour in mice following a 
reduced exposure to TRP depletion (P0 to P8)(Zoratto et al., 2011; Zoratto et al., 
2013) it is unclear whether a longer exposure would have had a greater effect. 
An alternative could be the 5-HT1a receptor antagonist WAY100635, which 
rescued depression-like behaviour in SERT-/- mice (Alexandre et al., 2006). 
While its administration also comprises injection-stress, it is likely to be less 
harsh on the pups than pCPA, given it is not a neurotoxin, and therefore may 
indeed be a viable alternative to rescue severe anxiety-like behaviour in the 
SERT-/- rat.  
Further research is required to determine whether the increased 
sensitivity to psychostimulants displayed by SERT-/- rats can also be rescued 
through decreasing excessive extracellular 5-HT during early development. 
However, given that neonatal TRP depletion could only rescue mild anxiety in 
male SERT-/- rats, and that sensitivity to psychostimulants is a much more 
robust behaviour than anxiety, it is likely a stronger manipulation, possibly a 
neonatal 5-HT1a receptor antagonist treatment, will be required. 
Unlike in the open field task, neonatal TRP depletion failed to rescue the 
anxiety-like phenotype displayed by male SERT-/- rats in the NSF task. However, 
there was an effect in females, with TRP depletion leading to an increased 
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latency to feed, regardless of genotype. These findings are in line with those 
observed in Sprague-Dawley rats in the pilot experiment (Experiment 1), which 
indicated that neonatal TRP depletion led to an increase in anxiety-like 
behaviour in the NSF task (but not in the open field task). These finding indicate 
that both increased as well as decreased neonatal 5-HT can lead to similar 
pathological phenotypes, and are in line with previous studies on both neonatal 
TRP depletion (Zhang et al., 2006; Zoratto et al., 2013) and SSRI exposure 
(Ansorge et al., 2008; Ansorge et al., 2004; Olivier et al., 2011). Taken together, 
these data demonstrate that both increasing and decreasing 5-HT during early 
development can lead to an increase in anxiety-like behaviours. Moreover, in 
addition to disruptions in emotion related behaviours, results from the pilot 
study (Experiment 1) indicate neonatal TRP depletion may lead to increased 
sensitivity to the psychomotor effects of amphetamine, which is in line with 
previous indications that neonatal SSRIs lead to increased sensitivity to the 
reinforcing effects of cocaine (Forcelli & Heinrichs, 2008). Thus, it is tempting 
speculate that an optimal level of 5-HT during development may be necessary 
for normal neuronal development. 
Unexpectedly, there were no differences in mRNA expression for long 
3’UTR BDNF or 5-HT1a, in either sex, between genotypes or following neonatal 
TRP depletion. This is in contrast with our hypothesis that the mRNA levels of 
both these genes would be down-regulated in SERT-/- rats, and unaffected in 
SERT-/- rats that had been exposed to neonatal TRP depletion. Previous studies 
in SERT-/- rats have indicated that long 3’UTR BDNF mRNA is decreased in male 
SERT-/- rats in the hippocampus from P0 and the PFC from P7 (Calabrese et al., 
2013), and in the ventromedial, but not the dorsomedial, PFC in adults 
(Calabrese et al., 2015). Given that the current study measured long 3'UTR 
BDNF mRNA in the whole PFC, not differentiating between these two regions, it 
is possible any differences in the present study were averaged out. Future 
studies ought to examine different regions of the PFC, as well as the mRNA 
levels of different BDNF transcripts, for which differences between genotypes 
have also been observed (Calabrese et al., 2015; Calabrese et al., 2013; Molteni 
et al., 2010). Furthermore, although the total number of 5-HT1a receptors is 
down-regulated in SERT-/- rats (Homberg et al., 2008), given the results of the 
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current study, it is possible the transcription of 5-HT1a mRNA is unaffected. 
This suggests a regulatory mechanism for this down-regulation, such as 
receptor internalisation, increased degradation, or a failure to translate the 
receptor. Further research is required to determine the exact mechanism of this 
down-regulation.  
Due to animal number constraints, monoamine levels following neonatal 
TRP depletion in SERT-/- rats were not assessed. Consequently, it is unknown 
precisely how neonatal TRP depletion affected the levels of monoamines in 
SERT-/- rats. However, given that SERT-/- rats have increased extracellular 5-HT, 
it’s likely the effect of TRP depletion would have been much greater.  In 
addition, as significant differences in anxiety-like behaviour were found 
between TRP-deprived and control SERT-/- rats, this manipulation appears to 
have had a successful behavioural effect. However, it is unknown precisely the 
extent to which 5-HT levels were decreased in SERT-/- rats. Further studies are 
required to determine whether their levels were normalised to the levels 
usually found in SERT+/+ rats or just decreased. 
Overall, the results from the current experiment indicate a mild, but not 
severe, anxiety-like phenotype in male SERT-/- rats can be rescued through 
decreasing 5-HT during neonatal development. While the mechanism for this 
alteration is as yet unknown, it is possible that an optimal level of 5-HT is 
necessary for normal brain development. 
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Chapter 5: General Discussion 
 
 
1 in 4 people, like me, have a mental health problem. 
Many more people have a problem with that. 
 
― Stephen Fry 
 
Although the lifetime rates for mental illness are staggering, as high as 1 in 3 
in New Zealand (Oakley Browne et al., 2006), substantial stigma exists toward 
individuals suffering from mental illness. Indeed, drug addiction and alcoholism 
are commonly perceived as self-inflicted (Crisp, Gelder, Rix, Meltzer, & 
Rowlands, 2000), and a common mantra in New Zealand is that individuals with 
depression just need to ‘harden up’. Moreover, individuals suffering from some 
forms of mental illness, such as schizophrenia and drug addiction, are thought 
to be dangerous and unpredictable (Crisp et al., 2000). This pervasive stigma 
provides significant barriers to recovery. For instance, it leads to lowered self-
esteem, and makes it more difficult to obtain work and find stable housing 
(Corrigan, 2004; Link, Struening, Neese-Todd, Asmussen, & Phelan, 2001), in a 
population that already suffers from these difficulties due to their illness. 
However, there is no scientific evidence to back up the notion that mental 
illness is a choice. Instead, complex interactions between an individual’s genetic 
and environmental backgrounds lead to an increased predisposition for mental 
illness in most individuals. For instance, as opposed to being self-inflicted, 
addiction is better described as a complex brain disorder, characterised by a 
loss of control, leading to the compulsive use of psychoactive substances despite 
negative consequences. As outlined in Chapter 1, the neurotransmitter 
serotonin (5-HT) is thought to be implicated in many psychiatric disorders. For 
instance, antidepressants that inhibit the 5-HT reuptake transporter (SERT) are 
commonly prescribed to treat a multitude of psychiatric disorders, including 
depression, anxiety, and anorexia nervosa. Moreover, the loss of function allele 
of the 5-HTTLPR (the short (s-) allele) has been associated with narcissism, 
anxiety, bipolar disorder, major depression, and increased drug dependence 
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(Cao et al., 2013; Caspi et al., 2003; Enoch et al., 2011; Gerra et al., 2007; Heils et 
al., 1996; Lesch et al., 1996; Sen et al., 2004). 
Consequently, the overall aim of the current thesis was to determine 
whether dysregulation of 5-HT is directly linked to the occurrence of psychiatric 
disorders, particularly drug dependence and anxiety. Studies using humans can 
only elucidate a correlation between variables, not causal relationships. Indeed, 
it is entirely possible that an independent variable leads to both 5-HT 
dysregulation and psychiatric disorders. However, rodent models, in which 
variables can be more tightly controlled and directly manipulated, can be used 
to establish causation. While low SERT expressing genotypes found in humans, 
such as the s-allele, do not naturally occur in rodents, genetic models have been 
created in which the SERT allele is knocked out (SERT-/-) (Bengel et al., 1998; 
Smits et al., 2006). Unlike s-allele carrying humans, who only show a 50% 
reduction in SERT activity (Lesch et al., 1996), SERT-/- rats have no SERT 
protein whatsoever. However, there are similarities in their phenotypes: As 
with human that have low SERT expressing genotypes, SERT-/- rats demonstrate 
anxiety- and depression-related behaviours (Olivier et al., 2008), although the 
presentation of these behaviours is strain dependent in SERT-/- mice. For 
instance, while SERT-/- mice on a C57BL/6J background show no apparent 
depression-like behaviour (Holmes et al., 2002; Kalueff et al., 2006), on a 129S6 
background, SERT-/- mice display a depression-like phenotype in the forced 
swim test, but an anti-depressant response in the tail suspension test (Holmes 
et al., 2002; Lira et al., 2003). Conversely, SERT-/- mice on a C57BL/6J 
background exhibit anxiety-like behaviour (Holmes et al., 2003), while on a 
129S6 background, SERT-/- mice display no anxiety-like behaviour in the open 
field or elevated plus maze tasks, although they do in the novelty supressed 
feeding (NSF) task (Lira et al., 2003), indicating that both species and genetic 
background can influence phenotype. 
Additionally, as with s-allele carriers, who show increased abuse of cocaine 
(Cao et al., 2013; Enoch et al., 2011), SERT-/- rodents show increased sensitivity 
to the reinforcing properties of cocaine (Homberg et al., 2008; Sora et al., 1998). 
Although, unlike SERT-/- rats, SERT-/- mice do not display increased cocaine-
induced psychomotor activity (Homberg et al., 2008; Sora et al., 2001). 
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However, these increased effects of cocaine in SERT-/- rodents are not 
particularly dramatic, and are indeed only seen at low but not high doses 
(Homberg et al., 2008). This is likely due to the relatively strong reinforcing 
effects of cocaine. Consequently, determining genotype responses to a less 
reinforcing drug of abuse, such as (±) 3, 4-Methylenedioxymethamphetamine 
(MDMA), was proposed in the current thesis. 
MDMA acts upon the reuptake transporters of 5-HT, dopamine (DA), and 
norepinephrine (NE) by both blocking the transporters and inducing reverse 
transport, to increase extracellular neurotransmitter levels (Crespi et al., 1997). 
However, unlike traditional psychostimulants such as cocaine and 
methamphetamine, which exert most of their effects on DAT, MDMA has a much 
higher affinity for SERT (Han & Gu, 2006). This increased propensity for the 
SERT compared with traditional psychostimulants is thought to underlie its 
reduced abuse potential (Callaway, Wing, & Geyer, 1990; Fantegrossi et al., 
2002; Schenk et al., 2007). Although no studies have previously looked at the 
effects of MDMA in SERT-/- rats, there have been a limited number of studies 
using the mouse model. These studies show that both the self-administration 
and the psychomotor effects of MDMA are abolished in SERT-/- mice (Bengel et 
al., 1998; Trigo et al., 2007). However, there are a number of differences 
between rats and mice which may mean that these findings do not translate to 
the rat model or humans. For instance, MDMA acts as a selective DA neurotoxin 
in mice but a 5-HT neurotoxin in rats, which is more similar to humans, as the 
SERT is down-regulated in current MDMA users (Buchert et al., 2003; Buchert et 
al., 2004; Colado et al., 2004; Easton & Marsden, 2006; Kindlundh-Högberg et 
al., 2007; O'Callaghan & Miller, 1994; O'Shea et al., 2001; O'Shea et al., 1998). 
Consequently, it is important to assess the effects of MDMA in the rat model 
also. Given the complex behavioural profile of MDMA in rats compared to 
traditional psychostimulants, in addition to its influence on 5-HT, DA, and NE, 
the current thesis aimed to use SERT-/- rats to investigate which of the 
behaviours were mediated by SERT and which are not. 
Consequently, Chapter 2 investigated the response of SERT-/- to several 
behavioural tasks that MDMA has previously been shown to disrupt. The results 
indicated that MDMA-induced disruption of startle habituation was abolished in 
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SERT-/- rats for 5 mg / kg, but not 10 mg / kg MDMA. The lack of effect for 10 mg 
/ kg MDMA is likely to do with learning (see Chapter 2 for more detail). Indeed, 
subsequent data collected in our laboratory group has shown the same effect of 
MDMA-induced disruption of startle habituation in experimentally naïve 
SERT+/+ rats with 10 mg / kg MDMA. These findings indicate that the SERT is 
necessary for MDMA-induced disruption of startle habituation, and are in line 
with previous pharmacological studies that showed these tasks are mediated by 
5-HT (Kehne et al., 1992). Moreover, the increase in ambulation and stereotypy 
following MDMA was unaltered in SERT-/- rats, although there was a trend for a 
diminished stereotypic response following MDMA compared to SERT+/+ rats. 
These findings indicate that the SERT is not required for MDMA-induced 
locomotor activity, in spite of previous pharmacological studies indicating that 
MDMA-induced locomotor activity is mediated by 5-HT as well as DA (Daniela et 
al., 2004; Kehne et al., 1996). However, these differences are likely mediated by 
the lack of target specificity in the pharmacological antagonistists used in these 
studies (see page 25 for further detail). Finally, in the drug discrimination 
paradigm, those SERT-/- rats that could discriminate between saline and low 
dose MDMA in the training phase fully generalised low dose MDMA to 
amphetamine, while only partial generalisation was observed in control rats. 
These findings indicate that 5-HT is essential for discriminating low dose 
MDMA, and also suggest that in SERT-/- rats the discriminative stimulus 
properties of MDMA are mediated via DA. However, only a small number of 
SERT-/- rats could learn to discriminate low dose MDMA from saline. This is 
likely due to the very small dopaminergic increase achieved following a low 
dose of MDMA, which did not enable most of the SERT-/- rats to reliably 
differentiate MDMA from saline. Overall, the findings from Chapter 2 indicate 
that the response to MDMA-induced disruption of tasks that pharmacological 
studies had previously indicated were predominately mediated by 5-HT are 
abolished in SERT-/- rats. 
Given that those SERT-/- rats that could discriminate between saline and low 
dose MDMA could not discriminate between MDMA and amphetamine, it was 
postulated that SERT-/- rats might show an increased propensity to self-
administer standard doses of MDMA. This was the focus for Chapter 3. 
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Strikingly, while only around half of SERT+/+ rats learned to self-administer 
MDMA, a finding in keeping with previous studies (Schenk et al., 2003), all of the 
SERT-/- rats acquired MDMA self-administration. Moreover, upon acquisition, 
SERT-/- rats obtained higher amounts of MDMA, and expended increased efforts 
to obtain the drug. These results indicate that SERT-/- rats are indeed more 
sensitive to the reinforcing effects of MDMA. These findings are consistent with 
the theory proposed by Bradbury et al. (2013) that a reduction in normal 
MDMA produced increases in 5-HT neurotransmission is required for the 
acquisition of MDMA self-administration.  
Overall, both humans and rodents with a down-regulated SERT function 
display pathological phenotypes in adulthood. However, the mechanism 
underlying this change is unclear. Consequently, Chapter 4 investigated the role 
of increased 5-HT during early brain development in the SERT-/- rats. It is 
paradoxical that humans and rodents with low functioning SERT genotypes 
would display increased risk of anxiety, depression, and drug abuse given that 
selective SERT blocking drugs (SSRIs) result in a decreases in these behaviours, 
e.g. (Carroll et al., 1990a). However, while individuals taking SSRIs do so largely 
in adulthood, individuals with low SERT expressing genotypes display increased 
extracellular 5-HT from very early on in development. Indeed, when 
extracellular 5-HT is normalised in SERT-/- mice in the two weeks following 
birth using the 5-HT neurotoxin para-chlorophenylalanine (pCPA), their 
disrupted rapid eye movement (REM) sleep is rescued (Alexandre et al., 2006). 
While the effect of normalising 5-HT has not yet been performed with emotion 
related behaviours, and never with SERT-/- rats, there are indications that 
preventing the activation of the 5-HT1a receptor by excessive 5-HT in SERT-/- 
mice rescues their depression-like behaviour (Alexandre et al., 2006). 
Moreover, the anxiety-like behaviour of 5-HT1a-/- mice is reversed when the 5-
HT1a receptor is restored during early development, but not adulthood (Gross 
et al., 2002), supporting a significant role of 5-HT neurotransmission during 
development in mediating normal anxiety-like behaviour. While being a 
relatively new rodent model of low functioning SERT allele, the SERT-/- rat is 
distinct from the mouse model in a number of ways. In addition to the 
aforementioned species difference in the effects of MDMA, 5-HT1a receptor 
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function differs between mice and rats, with 8-OH-DPAT induced hypothermia 
mediated presynaptically in mice, and postsynaptically in rats (Bill et al., 1991). 
Consequently, it is imperative to investigate whether the pathological 
behaviours displayed by SERT-/- rats are due to increased neonatal 5-HT during 
development. 
Accordingly, the aim of Chapter 4 was to determine whether neonatally 
lowering the excess extracellular 5-HT in SERT-/- rats would rescue their 
anxiety-like behaviour in adulthood as well as mRNA levels of both long 3'UTR 
Brain-derived neurotrophic factor (BDNF) and 5-HT1a in the prefrontal cortex, 
genes predicted to be down-regulated in SERT-/- rats. In order to avoid both 
injection stress in young pups, as well as the adverse effects of pCPA observed 
in a pilot study, neonatal TRP depletion, a more mild reduction of 5-HT, was 
selected. Following neonatal TRP depletion, male, but not female, SERT-/- rats 
showed increased time spent in the centre of the open field compared to their 
SERT+/+ counterparts that was not mediated by an increase in exploration. 
However, while SERT-/- rats displayed an increased anxiety-like phenotype in 
the more anxiogenic novelty supressed feeding paradigm, this was unaltered by 
neonatal TRP depletion. These results indicate that decreasing neonatal 5-HT in 
male SERT-/- rats normalises their anxiety-like behaviour in low anxiety, but not 
high anxiety, situations. Future studies are required to determine whether 
normalising neonatal 5-HT will rescue addiction-like behaviour in these 
animals. However given that neonatal TRP depletion was unable to rescue high 
anxiety-like behaviour in these animals, it is likely a stronger manipulation will 
be required, such as neonatal 5-HT1a receptor blockade.  
Unexpectedly, there were no differences in mRNA expression for long 
3'UTR BDNF or 5-HT1a, in either sex, between genotypes, or following neonatal 
TRP depletion. This is in stark contrast to previous studies indicating that long 
3'UTR BDNF mRNA is decreased in the ventromedial, but not dorsomedial PCF 
in adult male SERT-/- rats (Calabrese et al., 2015). Given that the current study 
measured long 3'UTR BDNF mRNA in the whole PFC, not differentiating 
between these two sections, it is possible any present differences were 
averaged out. Furthermore, these findings are also opposed to those indicating 
that binding of the 5-HT1a receptor is down-regulated in SERT-/- rats (Homberg 
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et al., 2008). However, given the results of the current study, it is possible the 
transcription of 5-HT1a mRNA is unaffected, suggesting a regulatory 
mechanism such as receptor internalisation, increased degradation, or a failure 
to translate the receptor. See table 5.1. for a summary of the findings of the 
current thesis.  
 
Table 5.1. Overall findings for SERT-/- rats  
Effect Outcome 
MDMA induced disruption of PPI − 
MDMA induced disruption of startle habituation  
MDMA induced locomotor hyperactivity − 
Discrimination of MDMA and saline  
Discrimination of MDMA and amphetamine 
MDMA self-administration  
Neonatal TRP depletion rescue of mild anxiety  
Neonatal TRP depletion rescue of severe anxiety − 
5-HT1a mRNA − 
long 3'UTR BDNF mRNA − 
Increase in SERT-/- rats, Decrease in SERT-/- rats, −    No change in SERT-/- rats. Note: due 
to the decreased discrimination of MDMA and saline, fewer SERT-/- rats met the discrimination 
criterion required to move on to the amphetamine probe trial. 
 
Overall, the results of the current study suggest that at least some of the 
behaviours observed in SERT-/- rats are likely due to an increase in perinatal 
extracellular 5-HT levels, rather than to high levels of 5-HT during actual 
testing. This is consistent with other studies which have demonstrated that 
postnatal SSRI exposure in rodents leads to increased anxiety- and depression-
like behaviours, as well as increased sensitivity to the reinforcing properties of 
cocaine (Ansorge et al., 2008; Ansorge et al., 2004; Forcelli & Heinrichs, 2008; 
Olivier et al., 2011), while SSRI use in adulthood is commonly used to decrease 
anxiety and depression. The ensuing question then is how excessive neonatal 5-
HT leads to emotion- and drug-dependant related behaviours in adulthood. 
Although this was not specifically investigated in the current thesis, it may be 
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due to the neurotrophic role of 5-HT. Given the wide role 5-HT plays in neural 
development, particularly in neuronal migration, division, and differentiation 
(For review see (Gaspar et al., 2003)). For instance, postnatal SERT blockade 
leads to altered dendrite morphology, as well as altered excitability of 
pyramidal neurons associated with fear extinction, in the medial PFC (Rebello et 
al., 2014). Moreover, there is significant interaction between 5-HT and the 
neurotrophic growth factor BDNF, which also plays a significant role in neural 
development. For instance, SSRIs increase BDNF in both rats and humans (Chen, 
Dowlatshahi, MacQueen, Wang, & Young, 2001; Nibuya, Morinobu, & Duman, 
1995). Moreover, BDNF is decreased in the PFC and ventral hippocampus of 
SERT-/- rats from very early on in development (P7-14) (Calabrese et al., 2013), 
while the addition of maternal separation (an early life stressor) reduces BDNF 
levels in the ventral hippocampus of mice heterozygous for the SERT gene 
(SERT+/-) (Calabrese et al., 2015). Consequently, it is possible that alteration of 
BDNF by the genetic reduction of SERT in these rats plays a role in the 
development of pathological phenotypes. 
More generally, the results of the current thesis suggest that neonatal 
imbalances of 5-HT lead to an increased predisposition to develop psychiatric 
disorders in humans. Given the wide role 5-HT plays in neuronal development 
(Gaspar et al., 2003) it is possible that increased 5-HT during development does 
not lead to gross brain abnormalities, but to structural and therefore functional 
disconnectivity between brain regions. Such functional disconnectivity is now 
widely proposed to underlie many psychiatric disorders such as schizophrenia 
and autism spectrum disorder (Geschwind & Levitt, 2007; Stephan, Friston, & 
Frith, 2009). Indeed, s-allele carriers show reduced functional connectivity 
between the perigenual anterior cingulate cortex and the amygdala, a circuit 
involved in emotional regulation (Pezawas et al., 2005). Moreover, the 
magnitude of disconnectivity was found to predict variation in harm avoidance, 
a trait associated with both anxiety and depression.  
Additionally, given the results of Chapters 2 and 3, it is possible that 
individuals with low SERT expressing genotypes are predisposed to finding 
psychostimulants more reinforcing, which may explain why they are more likely 
to abuse cocaine and methamphetamine (Cao et al., 2013; Enoch et al., 2011; 
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Gerra et al., 2007). If this is indeed the case it would likely be recommended 
these individuals avoid consuming drugs in the first place. Of course, the flip 
side is that individuals who do not have low SERT expressing genotypes may 
interpret such advice as indicating they are immune from the risks of drug 
dependence. This would be a precarious conclusion however, given that there 
are indications the l-allele is sometimes the risk allele depending on ethnicity 
(Cao et al., 2013), as well as patently disregarding the probable multitude of 
other genetic and environmental causes of drug dependence. However, that is 
not to ignore the logical conclusion that if susceptibility to drug addiction could 
be accurately predicted, one would know precisely whether one would become 
drug dependent or not. It is possible this information would lead to increased 
drug taking by unaffected individuals. However, it is important to note addiction 
is not the only harm associated with drug taking, and the medical risks of 
ingesting illicit drugs should also be considered. This issue is particularly salient 
given the increasing popularity of direct-to-consumer genomic testing (e.g. 23 
and me [www.23andme.com]). These test kits allow individuals to have their 
genome screened for known polymorphisms. Consequently, consumers are able 
to have access to more genetic information than ever before, and can 
proactively change their behaviour accordingly. However, these kits have come 
under considerable controversy, predominantly criticised for supplying access 
to medical information without accompanying guidance from a medical 
professional, potentially leading to gross misinterpretations. While the FDA no 
longer allows medical information to be provided in the US, raw data can be 
easily uploaded to an Internet database to obtain information on known 
medical associations. Consequently, information regarding polymorphisms will 
be more and more sought after. 
Furthermore, the results imply that individuals should be aware of the 
potential risks of SSRI use during pregnancy. There have been suggestions from 
animal studies that neonatal SSRI use leads to increases in pathological 
behaviour, such as anxiety, depression, and sensitivity to cocaine, in adulthood 
(Ansorge et al., 2008; Ansorge et al., 2004; Forcelli & Heinrichs, 2008; Olivier et 
al., 2011). However, human studies have been unable to answer similar 
questions due to short follow up periods, although gestational SSRI has been 
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associated with increases in autism and behavioural problems in children 
(Harrington et al., 2014; Oberlander et al., 2010). Given that the results of the 
current thesis strengthen assertions from animal literature that neonatal SSRI 
exposure leads to adult pathology, there is a need for longitudinal studies to 
determine whether the same occurs for humans.  
Given that the s-allele of the 5-HTTLPR has been linked to an increase in risk 
of psychopathology, its continued existence in the gene pool is puzzling. Indeed, 
given that the variation is particularly ancient, approximately 40 million years 
old (Lesch et al., 1997), it is unlikely that the variation evolved too recently to 
have been selected out. Consequently, it is likely that the s-allele is associated 
with positive outcomes in some circumstances. For instance, it has been 
proposed that, as opposed to displaying an overall increased risk for 
pathological behaviours, s-allele carriers display increased reactivity to the 
environment. For instance, an increase in the number of stressful life events has 
been positively correlated with depression in s-allele, but not l-allele, carriers 
(Caspi et al., 2003). Significantly however, follow up studies have demonstrated 
that this reactivity to the environment occurs with positive environments as 
well. For instance, supportive early life environments in s-allele carriers have 
been correlated with positive affect in children, and a decrease in depressive 
symptomology in young adults, compared with l-carriers (Hankin et al., 2011; 
Taylor et al., 2006). These findings indicate that, as opposed to being a ‘risk 
allele’, the s-allele is more likely a ‘plasticity allele’ given its responsiveness to 
changing environments, for better or for worse. The l–allele on the other hand is 
much more robust in the face of environmental changes.  
It has been speculated that the mechanism underlying these changes is 
altered activity in corticolimbic structures in s-allele carriers (Homberg & Lesch, 
2011). For instance, s-allele carriers display increased baseline amygdala 
reactivity that correlates positively with life stress (Canli et al., 2006). This is 
speculated to result in hyper vigilance to the environment (Homberg & Lesch, 
2011). Indeed, individuals with the s-allele show bias toward both positive and 
negative stimuli (Beevers, Ellis, Wells, & McGeary, 2010; Beevers, Gibb, 
McGeary, & Miller, 2007), although when a triallelic distinction is used, 
individuals with the low functioning SERT genotype show a bias toward angry 
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faces, while high functioning SERT genotypes show a bias toward happy faces 
(Pérez-Edgar et al., 2010). This hyper vigilance is likely adaptive given a positive 
environment but maladaptive given a negative one. Interestingly, individuals 
with mood disorders show similar neuronal dysregulation in corticolimbic 
areas. For instance, depressed patients also show increased amygdala activity 
(Drevets et al., 1992; Sheline et al., 2001), giving strength to the argument that 
these neuronal dysregulations are causative. While it is currently unclear why 
some individuals with a low functioning SERT genotype become anxious, while 
others become depressed or addicted to drugs, it is possible this hyper vigilance 
to the environment plays a role. For instance s-variant individuals may 
demonstrate increased attention toward stressful life events, leading to an 
increase in rumination, followed by an increase in depression (Canli et al., 2006; 
Caspi et al., 2003). Additionally, following exposure to drugs of abuse, s-variant 
individuals may be biased toward the positive effects of these substances, 
thereby finding them more reinforcing and being biased toward taking more of 
them (Homberg & Lesch, 2011). 
Finally, while the current thesis used a rat model of the 5-HTTLPR to model 
low functioning SERT in humans, this is not perfectly analogous to the human 
genotype. As the 5-HTTLPR does not normally occur in rodents, the SERT was 
genetically knocked-out to create a model of the polymorphism. While the 
heterozygous version of the model, like humans with the s/s genotype, have 
50% lowered transcriptional efficiency of the SERT gene (Homberg et al., 2007; 
Lesch et al., 1996), the full knock-out, containing no SERT protein whatsoever, 
was used in the current thesis in order to ensure proof of concept.  Given the 
increasing support for the idea that the environment is imperative to these 
pathological phenotypes, it is probable that with the full knock-out the genetic 
influence is so extreme that this is not required. Indeed, this would explain why 
the SERT-/- animals display increases in all measured pathological behaviours 
while humans with the low SERT expressing genotype do not. Consequently, the 
experiments ought to be repeated in the heterozygous model. Moreover, the 
addition of either negative or positive life events would allow it to be elucidated 
whether the s-allele is indeed a plasticity gene. While it is possible that the 
presence of one SERT allele is enough to compensate for decreased SERT gene, 
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and indeed, this seems to have mostly occurred with cocaine (Homberg et al., 
2008), preliminary data from our lab indicated a gene dose effect occurs in the 
self-administration of MDMA in these rats (Brox & Ellenbroek, unpublished 
data).  
 
Conclusions 
The current thesis found that genetic removal of the SERT resulted in an 
alteration in the behavioural effects of MDMA. This genetic removal resulted in 
an abolishment of MDMA-induced disruption to startle habituation, but failed to 
affect MDMA-induced increases in locomotor activity, implying that the SERT is 
necessary for MDMA’s disruption of startle habituation but not its psychomotor 
effects. Moreover, for those rats that could discriminate low dose MDMA from 
saline, genetic removal of the SERT resulted in the inability to discriminate 
MDMA from amphetamine, implying that, in these rats, MDMA was now 
subjectively indistinguishable from amphetamine. Indeed, this alteration also 
resulted in enhanced sensitivity to the reinforcing properties of MDMA, giving 
MDMA the qualities of traditional psychostimulants in SERT-/- rats. These 
findings support studies in humans with genetically reduced SERT that indicate 
these individuals demonstrate an altered response to MDMA, and imply they 
may be more sensitive to its reinforcing effects. Although the genetic removal of 
the SERT results in enhanced extracellular 5-HT, the pathological phenotypes 
present in this rat are likely due to this increase occurring in early development, 
not its continued presence in adulthood. Lowering the excessive 5-HT during 
neonatal development in SERT-/- rats led to a rescue of mild, but not high, 
anxiety-like behaviour in males. However, mRNA levels of long 3’UTR BDNF and 
5-HT1a, genes associated with neurodevelopment, remained unchanged across 
genotypes and treatment groups. Overall, these findings contribute to the 
growing body of literature indicating that enhanced brain 5-HT during early 
development can lead to pathological behaviour in adulthood.  
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